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ROLE OF AKT2 IN CELL SURVIVAL, ESTABLISHMENT AND/OR MAINTENANCE 
OF COLORECTAL CANCER METASTASIS 
Ekta Agarwal, Ph.D. 
University of Nebraska Medical Center, 2016 
Advisor: Michael G. Brattain, Ph.D. 
There is extensive evidence for the role of aberrant cell survival signaling mechanisms in cancer 
progression and metastasis. Akt acts as a key signaling node that bridges oncogenic receptors to 
many essential pro-survival cellular functions, and is perhaps the most commonly activated 
signaling pathway in human cancer. Akt has three isoforms, Akt1, 2 and 3. Variable phenotypic 
differences are observed following the genetic inactivation and/or removal of the Akt isoforms, 
which suggests that the isoforms have distinct non-redundant functional characteristics despite 
sharing a high level of structural homology and similar mechanisms of activation.  
 The major goal of the work presented in this dissertation was to identify the role of Akt 
isoforms on cell survival, establishment  and/or  maintenance of  metastasis in colorectal cancer 
(CRC). Although there is an increase in the 5-year survival rate of CRC during early stages, the 
progress in the survival rate during the metastatic stage is still dismal, suggesting the need to 
develop anti-metastatic therapy. The work presented in this dissertation has led to the 
identification of Akt2, among Akt isoforms, as a major player for establishment and/or 
maintenance of  metastasis. shRNA-mediated knockdown of Akt2, not Akt1, causes reduction in 
metastatic burden in CRC. We show that loss of Akt2 upregulates Metastasis Suppressor 1 
(MTSS1) and inhibits the expression of anti-apoptotic genes, XIAP and survivin thus inhibiting 
cell survival which in turn could lead to reduction in metastatic potential of the cells. It has been 
shown that activated Akt stabilizes XIAP by S87 phosphorylation, leading to survivin/XIAP 
complex formation, caspase inhibition and cytoprotection of cancer cells. Extensive drug 
xiii 
 
development efforts and clinical evaluations are underway targeting the aberrant cell survival 
properties associated with PI3K/Akt signaling in regulating cancer progression and metastasis. 
Inhibition of Akt activation by small molecule kinase inhibitors is an attractive candidate for 
targeting aberrant cell survival associated with malignant progression and metastasis and could be 
effective in the treatment of CRC. In this dissertation work, we have used a kinase inhibitor of 
Akt, MK-2206, to inhibit phosphorylation of Akt. We provide novel mechanistic insights on MK-
2206-mediated cell death. MK-2206 showed an anti-tumorigenic role and led to a dual 
mechanism of cell death by inhibiting XIAP and survivin and by inducing Apoptosis Inducing 
Factor. 
 Additionally, strategies to inhibit Akt2 as opposed to the other two isoforms may provide a 
therapeutic approach for treatment of metastases. A negative correlation between Akt2 and 
MTSS1 in human primary colorectal cancer samples might be useful in identification of 
metastatic patients.  
 The work presented in this dissertation may assist in understanding whether loss of Akt2 
could be a mechanism of increasing cell death, thus leading to reduction in metastasis. 
Additionally, this work provides a new paradigm for MK-2206-mediated control of aberrant cell 
survival associated with IGF1R-dependent CRC that may offer new targets for enhancing cell 
death in cancer cells.  
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CHAPTER I 
 Introduction 
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1.1 Colorectal cancer and current therapies 
 
Colorectal cancer (CRC) is the third most common type of cancer and the second leading cause of 
cancer related deaths in United States. As per the reports of National Cancer Institute (NCI) it has 
been estimated that about 134,490 (70,820 men and 63,670 women) new cases of colorectal 
cancer will be diagnosed in 2016. This accounts for about 8% of all new cancer cases that will be 
reported in the year 2016. The number of new cases of CRC is 42.4 per 100,000 men and women 
per year. It is expected that there will be about 49,190 CRC related deaths this year, which 
accounts for 8.4% of all the cancer related deaths and 15.5 per 100,000 men and women per year.  
As per the reports of Surveillance Epidemiology and End Results (SEERS) the median age at the 
time of diagnosis is estimated to be 68 years. The relative survival of cancer patients compared to 
general patients shows a 5-year survival of about 64.9%.  
Reports from SEERS show an inverse relationship between stage distribution of CRC and 
its corresponding 5-year survival rate. A localized case of CRC where the tumor is confined to 
the primary site has a stage distribution of 39% and the corresponding 5-year survival rate is 
90.1%. Regional CRC stage, when the tumor spreads to regional lymph nodes has a stage 
distribution of 36% and 5- year survival rate of 70.8%. Metastatic cases of CRC, where the tumor 
has spread to distant sites as liver and lung has stage distribution of 20% and the 5-year survival 
rate drastically reduces to 13%. It is known that the lifetime risk for CRC is 51.2%. Thus, it 
becomes evident that 1 out of 20 individuals would be diagnosed with CRC in their lifetime. Race 
and ethnicity are two additional factors that affect CRC incidence and mortality. NCI has reported 
that the mortality rates amongst whites and African Americans are much higher than all other 
people of different races and ethnicity living in United States. 
The etiological and pathogenetic mechanisms responsible for CRC development are 
complex and heterogeneous. Dietary and life style risk factors in addition to inherited and somatic 
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mutations also contribute to development of CRC. A diet rich in unsaturated fats and red meat, 
excess alcohol consumption and reduced physical activity are some of the lifestyle risk factors for 
CRC (Potter 1999, Slattery 2000, Hawk and Levin 2005). Commonly colon cancer begins with 
formation of polyp in the inner lining of colon or rectum. Figure 1.1 shows the stages of 
progression of colon cancer. Over time this polyp grows into a tumor but it still remains confined 
to the inner wall in Stage 0 of CRC. This stage is completely curable and surgical removal of the 
polyp is the standard therapy.  In Stage 1 the tumor grows to outer layer of the colon wall and 
invades the submucosa; however surgery is the standard therapy in this stage also. It is known 
that there is a high 5 year survival rate both stages 0 and 1 of CRC. In Stage 2 tumor grows out of 
the wall but does not spread to the lymph nodes. Surgical resection of the colon is the common 
therapy for this stage; however some recent studies are focusing on adjuvant chemotherapy in this 
stage of colon cancer, although it is still controversial as it depends on the condition of the 
patient. Some reports have shown that 5 Fluorouracil (5FU) based chemotherapy causes a better 
overall survival of the patient as compared to surgery alone. Stage 3 is evident by presence of 
tumor cells in the lymph nodes. Surgery and Adjuvant chemotherapy is the standard treatment in 
this stage. During this stage the 5 year survival rate is 70%. Stage 4 is characterized by presence 
of cancer cells at distant sites such as liver and lung. This stage denotes distinct metastasis.  The 
standard treatment options for this stage are surgery (surgical ablation of liver and lung tumors), 
chemotherapy and /or targeted therapy.  
There are several screening tools to detect CRC as fecal occult blood test (FOBT), 
sigmoidoscopy, colonoscopy and digital rectal examination. Despite all these advancements about 
20% CRC cases are diagnosed at stage 4 i.e. when the tumor has already undergone metastasis. 
There are only 10 active and approved drugs for metastatic colon cancer patients as per the 
reports of NCI. These drugs can be used alone or in combination with other drugs. Most 
commonly used drugs are 5-FU, Oxaliplatin, Bevacizumab, FOLFOXIRI (a combination of 
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Fluorouracil, Leuvocorin, Oxaliplatin and Irinotecan) and Cetuximab. It has been reported that 
combination of these drugs has improved the survival rate of patients with stage 3 CRC. Small 
molecule inhibitors and monoclonal antibodies targeted against specific molecular pathways are 
also being used in combination with traditional treatments. Bevacizumab, which targets the 
angiogenic signaling and has been approved for the treatment of CRC. It has been shown to 
increase the 5-year survival rate. Although there has been increase in the number of drugs to treat 
CRC, we still need to identify more molecular pathways, so that small molecule inhibitors can be 
designed against them, that can then be used to treat CRC. 
 Figure 1.2 shows the model for colon cancer progression, which depicts a loss in the 
tumor suppressor and a gain in oncogenes leading to progression from stage 1 to stage 4 of CRC, 
however not much is known about the signaling pathways leading to distant metastasis. In this 
dissertation, we have identified one such molecular pathway, which can be targeted to inhibit 
maintenance of metastasis in CRC.  
1.2 Metastasis 
Metastasis is considered as a complex process, that occurs through a series of steps, which 
includes invasion, intravasation, transport through the circulatory system, arrest at secondary site, 
extravasation and growth in secondary organs (Mehlen and Puisieux 2006). The temporal course 
of metastasis varies in different cancer conditions, thus making it more difficult to diagnose 
cancer at early stages. It is believed that several genetic and epigenetic alterations help the cells to 
undergo metastasis. Cancer cells become addicted to certain processes as unlimited proliferative 
potential, tolerating cell division defects, maintaining progenitor like phenotypes thus leading to 
formation of oncogenically transformed cells (Hanahan and Weinberg 2000).  Cancer cell 
metastasis progress through multiple steps as shown in Figure 1.4.  
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Metastasis is the end product of an evolutionary process, in which interactions between 
cancer cells and their microenvironment lead to alterations in the behavior of the cells (Chiang 
and Massague 2008). We know that surgical resection in addition to therapy can cure primary 
tumors, however it is difficult to target metastasis because of its systemic nature and increased 
resistance to therapeutic agents.  Metastases is responsible for 90% of cancer deaths, thus it is 
important to understand the molecular pathways involved in metastasis to develop effective, 
targeted approaches to prevent and treat cancer metastasis. It is known that a very small 
population of cells from the primary tumor succeeds in infiltrating, surviving and ultimately 
overtaking a distant organ (Fidler 2003) thus making a metastasis a highly inefficient process as 
shown in Figure 1.3.  
There are different classes of genes that play an important role in metastasis. They have been 
discussed as follows: 
1. Metastasis initiation genes: These genes could be present already in the primary tumor. 
The metastasis initiating genes help these transformed cells to invade the surrounding 
tissue and attract a supportive environment thus facilitating the dispersion of the cancer 
cells. These genes promote cell motility, epithelial to mesenchymal transition (EMT), 
extracellular matrix degradation, angiogenesis and evasion from immune system (Yang 
and Weinberg 2008). EMT markers Kiss-1 are some of the metastasis initiation genes 
(Nguyen, Bos et al. 2009) 
2. Metastasis progression genes: These are also a part of both primary tumor and 
metastasis, however unlike metastasis initiation genes, they play different role in primary 
tumor as they support tumor growth through one effect, whereas they enhance metastasis 
through other effect.  MMP-1, COX-2, EGFR are some of the metastasis progression 
genes (Nguyen, Bos et al. 2009). 
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3. Metastasis virulence genes: These genes are required for metastatic colonization in a 
specific organ. These genes increase the metastasis ability of the disseminated cancer 
cells that have achieved the stages of initiation and progression. It has been reported that 
these genes can lead to increase proliferation and survival solely during colonization at 
metastatic sites and would not be represented in the primary tumor. IL-11, TNK alpha, 
IL-16 are metastasis virulence genes (Nguyen, Bos et al. 2009). The different steps of 
metastasis are as follows: 
1. Local invasion: Cancer cells invade the surrounding tissue and attract a supportive 
stroma thus facilitating the dispersion of cancer cells. Recent studies show that well 
maintained architecture of normal epithelium tends to be a barrier for invasion. The 
metastatic cells have to overcome this barrier so that they can develop evident 
malignancies (Hu, Yao et al. 2008).  There are different ways of undergoing local 
invasion by cancer cells: collective invasion is the most common mechanism where 
cancer cells invade as multicellular units. Alternatively they can invade as individual 
cells via an integrin dependent or an integrin-independent (Rho/ROCK dependent) 
mechanism. The metastasis initiating genes play an important role in this step of 
metastasis as they promote cell motility, EMT and extracellular matrix degradation, so 
that the cancer cells can infiltrate the distant tissues (Yang and Weinberg 2008). EMT 
leads to breakdown of  tight junctions leading to loss in polarity of cell and dissociation 
of epithelial cell sheets leading to increased invasion of cells (Thiery, Acloque et al. 
2009). Once the cancer cells have crossed the basement membrane they encounter a 
variety of tumor associated stromal cells which further augments the aggressiveness of 
the cells (Joyce and Pollard 2009), thus the stroma helps the direct entry of the tumor 
cells into the circulation so that they propagate to distant sites. 
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2. Intravasation: In this step of metastasis, the cancer cells invade and move through the 
walls of the nearby blood vessels. This step is facilitated by molecular changes that 
promote the ability of cancer cells to cross the endothelial cells of the blood vessels 
(Gupta and Massague 2006). Cancer cells show increased cell survival during this step 
thus suggesting that entry of cells into the vasculature can be an important rate-limiting 
step of metastasis (Wyckoff, Jones et al. 2000). During this stage, vascular endothelial 
growth factors lead to formation of new blood vessels. This neovasculature is leaky and 
is very dynamic. The weak interaction between the endothelial cells and the 
microvasculature enables the cells to undergo intravasation (Carmeliet and Jain 2011). 
3. Circulation: In this stage the cancer cells move through the lymphatic system and blood 
stream, get arrested in the capillary bed and proliferate to reach the distant sites. The cells 
during this stage are referred as Circulation Tumor Cells (CTCs). The CTCs represent the 
cells that are between primary tumor and sites of dissemination and are also known as 
metastatic intermediates (Nagrath, Sequist et al. 2007). The lifespan of CTCs varies with 
type of cancer, but overall they spend a very small time in the circulation and get 
embedded in the capillaries (Meng, Tripathy et al. 2004).  During this stage the cancer 
cells have to pass through various types of stressful and selective steps as matrix 
detachment, shear forces and resistance from immune system (Joyce and Pollard 2009). 
Additionally, some recent reports show that CTCs are predetermined to enter certain 
tissues. In case of colorectal cancer, the entry of cells in the liver initiates a 
proinflammatory response that triggers the Kupffer cells to release certain molecules that 
activate the vascular adhesion receptors, thus leading to increased adhesion of CTC in the 
liver (Auguste, Fallavollita et al. 2007). 
4. Extravasation: When the CTCs reach distant organs they rupture the walls of the  
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surrounding vessels thus placing the tumor in direct contact with the tissue. Normally this 
step is considered to be a reverse of intravasation.   
5. Proliferation and Angiogenesis:  After extravasation, the cancer cells multiply at distant 
sites of the body and form micrometastases, which then lead to growth of new blood 
vessels. The formation of new blood vessels helps to supply oxygen and nutrients which 
are necessary for continuous tumor growth. During this step, the cancer cells adjust to the 
unfavorable foreign microenvironment by establishing a “pre-metastatic niche” (Psaila 
and Lyden 2009). This mechanism helps the cancer cells to evade the stress significantly 
but not completely. The proliferation potential of the cells is still very low and there is a 
fine balance between proliferation and apoptosis, thus leading to attrition of metastatic 
colonization (Chambers, Groom et al. 2002). The metastatic colonization is highly 
dependent on the ability of the cells to undergo neoangiogenesis and self-renewal. Thus 
overall these steps are affected by various signaling pathways (Valastyan and Weinberg 
2011). 
 Thus various genetic and epigenetic alterations help the carcinoma cells to complete these 
complex, biological steps that lead to formation of metastases. The mechanisms that help the 
cancer cells to survive after they reach distant organs and after being exposed to foreign 
microenvironments are not well known. Cell survival at this stage is considered as a rate-limiting 
step for the establishment of metastasis (Wong, Lee et al. 2001). A better understanding of the 
survival mechanisms is required to develop therapeutic strategies to eliminate metastasis after 
primary tumor has been removed. 
1.3 Cell survival regulators 
Apoptosis or ‘programmed cell death’ has been extensively studied over last few years.  It is 
known that apoptosis is a barrier to metastasis. During the process of metastasis the cells have to 
pass through various stresses as loss of adhesion: leading to detachment from extracellular matrix, 
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nutrient deprivation and hypoxia, all of which can lead to apoptosis. Cell death by the process of 
apoptosis involves the activation of cysteine proteases called caspases (Salvesen and Dixit 1997).  
Caspases have been divided into: initiator caspases and effector caspases. Effector caspases are 
cleaved and activated by initiator caspases thus leading to activation of apoptosis.  There are two 
main pathways for apoptosis: Extrinsic pathway (Death receptor pathway) and Intrinsic pathway 
(Mitochondrial-mediated pathway) (Zimmermann and Green 2001). 
 In the extrinsic pathway, activation of CD95 receptor or tumor- necrosis factor receptor 
(TNF) recruits the death-inducing signaling complex (DISC), which then activates initiator 
caspase: caspase-8. Cleavage of downstream effector caspases by caspase 8 leads to cell death.  
The intrinsic pathway involves the release of proteins from the mitochondria such as 
cytochrome c to induce cell death. Cytochrome c stimulates the formation of another caspase 
activating complex, apoptosome, which then activates the initiator caspase-9 leading to activation 
of downstream signaling pathway resulting in apoptosis. The BCL2 family members include both 
pro-apoptotic (BAX and BH3 only proteins) and anti-apoptotic (BCL2 and BCL-XL) proteins 
which play an important role in the release of cytochrome c. Activation of p53 (tumor suppressor) 
also lead to increase in the transcription of BCL2 family member proteins, leading to release of 
cytochrome c. The two pathways can function independently but there can be a cross talk 
between the two pathways in certain conditions.  Activation of caspase-8 via the extrinsic 
pathway sometimes fails to activate effector caspases but can efficiently cleave BID (BH3 
interacting domain death agonist), which then activates the intrinsic pathway of apoptosis. In 
addition to BCL-2 and Caspases, Inhibitor of Apoptosis proteins (IAPs) also contributes to 
apoptosis (Srinivasula and Ashwell 2008).  
1.3.1 Inhibitor of Apoptosis Proteins (IAPs) 
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Originally IAPs were identified in viruses as cellular proteins with a Baculoviral IAP Repeat 
(BIR) motif, a sequence of 70 amino acids that coordinates a zinc ion with histidine and cysteine 
residues (Srinivasula and Ashwell 2008). They were found to be involved in suppressing the host 
cell death response to viral infection (Deveraux and Reed 1999). Additionally, they also 
participate in mitotic chromosome segregation, cellular morphogenesis, copper homeostasis and 
intracellular signaling. IAP proteins are implicated in multiple ways in cell death regulation, 
ranging from inhibition of apoptosis and necrosis to the regulation of cell cycle and inflammation. 
Structural features of IAPs 
The BIR domain is the basic structural feature of IAPs. The IAP molecules may have one or 
multiple BIR domains at the N terminus. On the basis of presence of BIR domains, the IAP 
family has 8 members as shown in Figure 1.5. The C terminus of IAPs has the RING domain and 
the CARD domain (Caspase-associated recruitment domain). The Ring domain regulates cell 
death and functions as an E3 ubiquitin ligase. The anti-apoptotic role of the CARD domain has 
not been well studied, although it is known that IAPs with BIR domains are capable of blocking 
apoptosis. This implies that CARD domain is not essentially required for IAP function (Roy, 
Deveraux et al. 1997). 
1.3.2 X linked Inhibitor of Protein (XIAP) 
The XIAP member of IAP family is very well characterized. The gene encoding XIAP has a 
molecular weight of 57kDa. It is present on chromosome Xq24-25. Biochemical and structural 
analyses have revealed that XIAP has 3 BIR domains (Eckelman, Salvesen et al. 2006). These 
domains are 40% homologous to each other structurally but have striking differences in their 
functions. It is known that the BIR1 domain inhibits caspase 3 and 7, whereas the BIR 3 domain 
inhibits caspase 9 (Deveraux, Leo et al. 1999). BIR 1 and 2 domains have a conserved sequence 
known as the IAP binding motif (IBM) interacting domain, whereas this domain is absent in the 
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BIR 1 domain (Scott, Denault et al. 2005). XIAP is known to be the only IAP, that can inhibit 
caspase activity by direct physical interaction. On induction of apoptosis, Smac (also known as 
DIABLO) is released from the mitochondria and interacts with the BIR domains of XIAP to 
inhibit caspase inhibition (Chai, Shiozaki et al. 2001). The RING domain of XIAP has E3 
ubiquitin ligase activity, which is responsible for recognizing the substrates that are ubiquitinated 
by XIAP (Obexer and Ausserlechner 2014). The RING domain also controls the stability of 
XIAP and induces proteasomal degradation of bound proteins (Vaux and Silke 2005). The overall 
mechanism of inhibition of cell death by XIAP is shown in Figure 1.6. 
 In addition to the above-mentioned function, XIAP also plays an important role in NF-
kappa B and MAP kinase activation during TGF beta and BMP receptor signaling (Birkey 
Reffey, Wurthner et al. 2001). XIAP acts as a cofactor and bridges the TGF beta and BMP type 1 
receptors to TAK1. TAK1, a MAP3K, activates the MAPK and NF-kappa B signaling (Brown, 
Vial et al. 2005). Additionally, XIAP also regulates the Jun N- terminal kinase (JNK), Myc and 
PI3K/Akt pathways. The activation of these pathways by XIAP is mediated via TNF (Karin and 
Gallagher 2009).  This signaling pathway is essential for diverse developmental processes, 
regulation of apoptosis, and vascular development (Jadrich, O'Connor et al. 2003).    
 XIAP is differentially upregulated in various cancer conditions such as breast cancer, 
melanoma, clear-cell renal carcinoma, and colon cancer and it confers resistance to 
chemotherapy-induced cell death (Wilkinson, Cepero et al. 2004, Berezovskaya, Schimmer et al. 
2005),  however it has been also shown that there is a downregulation of XIAP on treatment with 
chemotherapy, as it undergoes autoubiquitination in response to DNA damage caused by 
chemotherapeutic agents (Deveraux and Reed 1999, Cheng, Jiang et al. 2002). Treatment with 
XIAP siRNA in combination with chemotherapy enhances chemosensitivity, thus suggesting that 
XIAP can be considered as a target for anticancer therapy (Andersen, Becker et al. 2005). Recent 
studies show that phosphorylation of XIAP by Akt regulates its ubiquitination and degradation. 
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Akt phosphorylates XIAP at Serine 87, thus stabilizing it by inhibiting its degradation, leading to 
inhibition of cell death (Dan, Sun et al. 2004). 
 Increased expression of XIAP has been associated with cancer progression (Fong, Liston 
et al. 2000, Gordon, Mani et al. 2007).The biological significance of increased expression of 
XIAP in cancer invasion and metastasis is still unknown. In hepatocellular carcinoma, loss of 
XIAP inhibits metastasis (Shi, Ding et al. 2008). Similarly, in colon cancer it has been reported 
that knockdown of XIAP inhibits invasion of cancer cells. XIAP shows its metastatic role as it 
affects cell motility via regulation of beta-actin polymerization and cytoskeleton formation. XIAP 
inhibits the biological effect of RhoGDI in regulation of Arp2/3 recruitment and beta actin 
polymerization (Liu, Zhang et al. 2011). Thus XIAP increases metastasis by inhibiting cell 
survival and increasing motility of cancer cells. Thus targeting XIAP can be a lead target to 
inhibit both survival and metastasis of cancer cells.  
1.3.3 Survivin 
Survivin is the smallest of the known IAP family proteins, as it contains a single BIR domain. It 
has a molecular weight of 16 kDa and is present on chromosome 17q25. Survivin prevents 
apoptosis by binding to caspases and inhibiting them. This IAP protein family member has been 
implicated both in cell survival and regulation of mitosis in cancer (Ambrosini, Adida et al. 1997, 
Giodini, Kallio et al. 2002).   
Survivin is highly expressed in multiple cancer types skin, pancreatic, colon cancer and 
lymphoma; however it has a very restricted expression in normal tissues (Ambrosini, Adida et al. 
1997). Loss of survivin leads to an increase in apoptosis and increased sensitization to anti-cancer 
drugs in cancer cells, thus suggesting that survivin may be required for cell survival and 
chemoresistance in various cancer conditions (Nakahara, Kita et al. 2007) and making survivin a 
target for tumor diagnosis, prognosis and therapy. The mechanism by which survivin inhbits 
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apoptosis is still not clearly known; however, some recent studies have delineated the mechanism 
of cell death inhibition by survivin. According to one study, it has been demonstrated that, in 
response to cell death, survivin physically associates with XIAP; this complex of XIAP and 
survivin increases the stability of XIAP thus leading to inhibition of caspase activity. It has been 
shown that survivin binds to the RING domain of XIAP and inhibits its polyubiquitination and 
proteosomal degradation. Increased stability of IAPs increase cell viability, as the stabilized 
survivin-XIAP complex suppresses caspase 9 activity, thus blocking apoptosis. Furthermore, 
survivin can sequester SMAC/DIABLO (mitochondrial activator of caspases), thus preventing 
inhibition of XIAP (Sun, Nettesheim et al. 2005) as shown in Figure 1.7.  
Survivin has also been known to play a role in mitosis.  It is known to affect the 
assembly/stability of metaphase and anaphase microtubules and spindle check point function 
(Giodini, Kallio et al. 2002). The chromosome passenger complex (CPC) is a key regulator of 
mitosis and survivin is one of the members of this complex, which includes Borealin, INCENP 
and Aurora B kinase (Jeyaprakash, Basquin et al. 2011). The expression of survivin varies in 
different stages of cell cycle, with highest expression during G2/M phase and declining rapidly in 
G1 phase (Li, Ambrosini et al. 1998). It has been shown that survivin-depleted cells can exit 
mitosis prior to segregation of sister chromatids.  
Recently, it has been determined that survivin undergoes phosphorylation at serine and 
threonine sites. Threonine phosphorylation of survivin inhibits its mitotic functions and increases 
its cytoprotective role (Barrett, Osborne et al. 2009), whereas phosphorylation at serine is 
required for alignment of chromosomes during mitosis (Colnaghi and Wheatley 2010). A 
phosphomimetic mutant of survivin (T34A) is not able to bind to and inhibit caspases, thus 
leading to an increase in cell death (O'Connor, Grossman et al. 2000). In addition to caspase- 
dependent cell death, loss of survivin is also responsible for caspase-independent cell death. 
Knockdown of survivin induces the translocation of AIF (Apoptosis Inducing factor) from the 
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cytoplasm to the nucleus, leading to caspase-independent cell death (Pavlyukov, Antipova et al. 
2011), whereas overexpression of survivin prevents the release of AIF thus leading to increased 
cell survival (Okuya, Kurosawa et al. 2009) as depicted in Figure 1.8. Identification of survivin 
signaling and its novel targets can lead to a better understanding of its role in cancer and its 
potential as an important cancer drug target. 
1.3.4 Apoptosis Inducing Factor (AIF) 
The AIF gene is mapped to chromosome Xq25-26 region in humans. It is translated to a 67 kDa 
precursor molecule which then undergoes folding to become mature AIF (Susin, Lorenzo et al. 
1999). It is a flavin adenine dinucleotide-containing, NADH-dependent oxidoreductase, that 
resides in the mitochondrial intermembrane space. The enzymatic activity of AIF is still 
unknown. AIF has three domains: an N-terminal mitochondrial localization sequence (MLS), a 
spacer of 27 amino acids, and a Carboxy-terminus with an oxidoreductase domain including the 
nuclear localization sequence (NLS) as shown in Figure 1.9 (Modjtahedi, Giordanetto et al. 
2006). 
 On induction of apoptosis, AIF undergoes proteolysis and translocates to the nucleus 
where it triggers chromatin condensation and large scale DNA degradation in a caspase 
independent manner (Susin, Lorenzo et al. 1999) as shown in Figure 1.10. Presence of AIF in the 
cytosol triggers the release of more AIF from the mitochondria, forming a positive feedback loop 
thus leading to increased apoptosis (Cai, Yang et al. 1998).  The release of AIF from the 
mitochondria is also guarded by anti-apoptotic Bcl-2 family protein (Daugas, Susin et al. 2000). 
These anti-apoptotic proteins reduce the permeabilization of the outer mitochondrial membrane 
thus preventing the release of cytochrome c and AIF and inhibiting both caspsase-dependent and 
caspase-independent cell death (Cande, Cecconi et al. 2002). Additionally, PAR polymer, the 
major product of PARP -1 activation, is a pro-death signaling molecule that causes release of AIF 
from the mitochondria, leading to nuclear condensation and cell death (Yu, Andrabi et al. 2006). 
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  In breast (Ostrakhovitch and Cherian 2005), lung (Kuhar, Sen et al. 2006), colon 
(Huerta, Harris et al. 2003), and prostate cancer (Fu, Zhang et al. 2006), it has been observed that 
treatment with chemotherapeutic agents induces apoptosis by increasing the depolarization of the 
mitochondrial membrane, leading to increased release of AIF (Lee, Jeong et al. 2006). Previous 
studies have shown that AIF plays a role in chemosensitization of cells resistant to cytotoxic 
induced apoptosis. Overexpression of AIF increases the sensitivity to chemotherapy, thus leading 
to chemotherapeutic drug-induced cell death (Fu, Qiu et al. 2006). All these studies indicate that 
AIF can be a prognostic marker and a target for chemotherapeutic intervention and an important 
molecule for increasing the chemosensitization in various cancer types (Millan and Huerta 2009). 
1.3.5 Ezrin 
Ezrin is a member of the ERM (Ezrin, Radixin, Moesin) protein family (Bretscher, Edwards et al. 
2002). These proteins share 70% sequence homology and have a common structure (Turunen, 
Wahlstrom et al. 1994). This structure consists of an NH2- terminal domain, an alpha-helical 
domain and an actin-binding COOH-terminal domain (Gould, Bretscher et al. 1989). In native 
state, the carboxyl domain and the amino-terminal domains self-associate, thus masking the F 
actin-binding domain (Pestonjamasp, Amieva et al. 1995). Ezrin is expressed in normal tissues 
and has been shown to play an important role in embryogenesis (Dard, Louvet-Vallee et al. 2004, 
Polesello and Payre 2004). In normal cells, Ezrin has diverse roles in villar organization in the 
gut, maintenance of photoreceptors, control of cortical stiffening during mitosis, and regulation of 
RhoA activity in epithelial cells (Saotome, Curto et al. 2004, Chorna-Ornan, Tzarfaty et al. 2005, 
Kunda, Pelling et al. 2008). ERM knockout mice can survive only for 21 days after birth (Kivela, 
Jaaskelainen et al. 2000). 
 Ezrin links F-actin to the cell membrane on phosphorylation, thus acting as a linker 
between plasma membrane and cytoskeleton (Sato, Funayama et al. 1992). In addition to F actin, 
it can also bind to CD44, phosphotidyl inositol 4,5 bisphosphate and intercellular adhesion 
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molecules (ICAMs), and the scaffolding protein ERM binding phosphoprotein 50 (EBP50) 
(Pakkanen 1988, Tsukita, Oishi et al. 1994, Heiska, Alfthan et al. 1998). Interaction of ezrin with 
ICAMs, suggest that it also plays a role in immune responses as ICAMs are responsible for 
initiating immune responses when stimulated with inflammatory cytokines (Fawcett, Holness et 
al. 1992, Vazeux, Hoffman et al. 1992). CD44 plays a role in migration of invasive tumors by 
inducing intracellular signaling, and interaction of ezrin with CD44 suggests that ezrin might be 
implicated in metastasis (Ponta, Sherman et al. 2003). Phosphorylation of the C terminus of ERM 
is required for their activation. Phosphorylation at threonine sites leads to an “open/active” 
conformation so that they can directly affect the cells (Geller and Gorlick 2011). In osteosarcoma, 
it has been reported that high expression of phosphor-ezrin is observed only at the invasive front 
of large metastatic lesions (Ren, Hong et al. 2011).  
  Ezrin is expressed on the cell surface to maintain the polarity of endothelial cells.  It is 
involved in cell-cell and cell-matrix interactions and thus plays an important role in 
tumorigenesis, development, invasion, and metastasis (Chen, Wang et al. 2011). Recent reports 
show that ezrin also participates in cell survival, proliferation, and migration processes. It is 
necessary for some signaling pathways that play an important role in metastasis, such as MAPK, 
Akt, Rho kinase, and CD44 (Chen, Wang et al. 2011). Active Rho A can recruit ROCK family 
members that phosphorylate cytoskeletal proteins such as members of ERM family, thus leading 
to increased membrane-cytoskeletal interaction (Bretscher, Edwards et al. 2002). In addition to 
coordinating-metastasis associated signaling events, ezrin also plays a role in cell adhesion and 
cell-cell communication (Pujuguet, Del Maestro et al. 2003).  Ezrin mediated formation of cell-
cell adhesion leads to increase in cell survival and helps to pass growth signals between the 
surrounding tissue and invading metastatic cells (Tsukita, Oishi et al. 1994). Ezrin leads to 
increased metastasis of cancer cells by various mechanisms, as it inhibits anoikis during 
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migration of cells (Bretscher, Edwards et al. 2002), or it sends sustenance signals to the cells 
when they enter in the harsh environment of the metastatic sites (Tsai, Mendoza et al. 2007).  
 Previous work from our lab has shown that there is an increase in the expression of 
phosphor-ezrin (T567) in liver metastasis in vivo as well as in human colorectal cancer patients. It 
has been reported that expression of phosphor-ezrin may be regulated by the IGF-1R signaling 
pathway and thus activation of this pathway may lead to increase in cell survival by modulating 
XIAP and survivin (Leiphrakpam, Rajput et al. 2014). Additionally, increased expression of 
phospho ezrin in the metastatic lesions of various cancers such as pediatric sarcoma (Khanna, 
Wan et al. 2004), breast (Li, Wu et al. 2008), colon (Leiphrakpam, Rajput et al. 2014) and ovarian 
cancer, brain tumors, and soft tissue sarcoma (Song, Fadiel et al. 2005) suggests that it can be a 
potential biomarker as well as a lead target for anti-metastatic therapy. 
1.4 Metastasis Suppressor Gene 1 (MTSS1) 
MTSS1, also known as MIM (missing in metastasis), has been identified as a tumor suppressor in 
various cancer conditions (Lee, Macoska et al. 2002, Ma, Guan et al. 2007). Figure 1.11 depicts 
the domain structure of MTSS1. The N terminal portion of MIM contains an IMD (IRSp53 MIM 
domain) that can bind to actin filaments and interact with the GTPase Rac. MIM overexpression 
induces Rac activation. MIM interacts with PTP (Protein Tyrosine Phosphatase) delta near its 
proline-rich region, thus regulating tyrosine phosphorylation-dependent signaling. MTSS1 
regulates the activity of Rac1 during cell-cell junction formation, thus localizing Rac1 GTP to 
these sites and strengthening cell –cell contacts, leading to reduced cell dissociation. It acts as a 
scaffold protein, which binds with actin binding protein thus regulating lamellipodia formation 
(Lin, Liu et al. 2005). It has been shown that MTSS1 affects cytoskeleton and actin filament 
organization (Mattila, Salminen et al. 2003).  It induces actin-rich protrusions resembling micro 
spikes and lamelliopodia at the plasma membrane and promotes assembly of actin fibers. The 
actin cytoskeleton plays a key role in regulating essential cellular processes such as cell 
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migration. Additionally, MTSS1 enhances Arp2/3-mediated actin polymerization by interacting 
with Cortactin. Overexpression of MTSS1 leads to disassembly of actin based cytoskeleton 
organization characterized by an increase in lamellipodia and filopodia plasma membrane 
protrusion and actin depolymerization whereas MTSS1 depletion disrupts the actin cytoskeleton 
thus increasing the ability of cells to disaggregate.  Thus, overall, MTSS1 increases the strength 
of cell-cell junction by blocking EMT (22479308). 
MTSS1 is associated with higher motility and invasiveness of cancer cells, thus resulting 
in faster infiltrative tumor growth and metastatic behavior (Loberg, Neeley et al. 2005). It is 
considered as a co-transcription factor which binds to GLI proteins and increases their 
transcription, thus leading to an increase in tumor cell growth and proliferation (Gonzalez-
Quevedo, Shoffer et al. 2005). It appears that MTSS1 is first overexpressed to promote 
carcinogenesis and then with ongoing tumor progression its downregulation results in more 
aggressive biological behavior (Kayser, Csanadi et al. 2015). MTSS1 overexpression results in 
reduction in tumor cell migration, invasion, and growth, and an increase in cell adhesion. It is 
believed that it also maintains the polarity of the cell by affecting cell adhesion (Mattila, 
Salminen et al. 2003) thus contributing to the maintenance of the integrity of epithelial tissues. 
MTSS1-deficient mice have defect in intercellular junctions of epithelial cells (Saarikangas, 
Mattila et al. 2011). 
It has been shown that patients expressing high levels of MTSS1 have a better prognosis 
(Parr and Jiang 2009), thus, indicating that MTSS1 is a survival indicator. Patients with 
oesophageal squamous cell carcinoma show high expression of MTSS1 and have a favorable 
prognosis in comparison to patients with low expression of MTSS1. In breast cancer, it has been 
observed that MTSS1 overexpression suppresses invasion, migration, and adherence, and governs 
metastasis (Parr and Jiang 2009).  
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There are 3 p63 binding sites on the promoter of MTSS1, as determined by CHIP-Seq 
assay (Giacobbe, Compagnone et al. 2015). It was observed that MTSS1 and delta NP63 are 
positively correlated and are negative prognostic factor in human tumors. Breast cancer patients 
with positive correlation show a decrease of overall survival of the patients as compared to those 
with no correlation between p63 and MTSS1, indicating that p63 and MTSS1 axis is a negative 
prognostic factor on patient survival and is important for tumor regression. Delta NP63 is 
associated with inhibition of migration and invasion of tumor cells but some reports indicate that 
it can be an oncogene and pro-invasive factor in breast cancer (Giacobbe, Compagnone et al. 
2015). 
The expression of MTSS1 is reduced in bladder, breast, and prostate cancer. This 
metastasis suppressor gene can be targeted by methylation and ubiquitination by DNMT3A (Yan, 
Yao et al. 2015) and beta-TRCP (Zhong, Shaik et al. 2013), respectively,  which then leads to 
reduction in the expression of MTSS1. Additionally, it has been also shown that it can also be 
targeted by microRNAs (Guo, Ren et al. 2015). All these studies suggest that MTSS1 can be an 
important marker for metastasis, although further studies are required to confirm it as a metastasis 
suppressor.  
1.5 Cortactin (CTTN) 
Cortactin is a cytoskeletal protein that interacts with F-actin, Arp2/3 complex and with other 
cytoskeletal proteins. It is composed of 3 major domains as shown in figure 1.12 (A): N terminal 
acidic (NTA) region that is responsible for binding and activation of Arp2/3 complex, a central 
tandem repeat of 37 amino acid sequence, and a C terminal domain which interacts with N-
WASP and MTSS1 (Shvetsov, Berkane et al. 2009). The CTTN gene is present on chromosome 
11, which normally shows altered expression in most cancers. It is ubiquitiously expressed in 
most hematopoietic cells (van Rossum, Schuuring-Scholtes et al. 2005). Its undergoes post 
translational modifications such as alternative splicing, phosphorylation and acetylation (Ohoka 
20 
 
and Takai 1998) leading to alterations in its functions. Loss of domains by alternate splicing leads 
to reduced affinity for F actin (Ohoka and Takai 1998), reduced localization with actin and 
reduced motility. Similarly acetylation by HDAC6 inhibits F actin binding and cell motility (van 
Rossum, de Graaf et al. 2003). CTTN is a substrate of Src tyrosine kinase, which phosphorylates 
it at Y421 and  Y466. Phosphorylation of the tyrosine residues stimulates the cleavage of CTTN 
by calpain and this cleavage appears to mediate CTTN-regulated protrusion of the cell edge 
(Perrin, Amann et al. 2006). Tyrosine phosphorylation of CTTN correlates with aggressiveness of 
cancer cells and is required for metastasis whereas inhibition of phosphorylation decreases cancer 
cell metastasis. Disruption of tyrosine phosphorylation sites prevents cell edge protrusion, cancer 
cell invasion and actin polymerization (Kelley, Hayes et al. 2010).  Tyrosine phosphorylation 
increases focal adhesion dynamics and leads to stress fiber disassembly (Kruchten, Krueger et al. 
2008), leading to increased motility of cancer cells.  
CTTN is also phosphorylated by several serine/threonine kinases. The serine/threonine-
protein kinase PAK3 phosphorylates it on S113 in response to growth factor receptor stimulation 
(Webb et al., 2006). PAK1 phosphorylates CTTN on S405 and S418 downstream of Rac1 and 
CDC42, which are members of the Rho family of small GTPases that are required for its 
localization to the cell edge and its increased association with N-WASP (Grassart et al., 2010; 
Vidal et al., 2002; Weed et al., 1998). Mitogen-activated protein kinase kinases (MEKs, also 
known as MAP2Ks) and extracellular signal-regulated kinases (ERKs, also known as MAPKs) 
have also been shown to phosphorylate CTTN on residues S405 and S418 (Campbell et al. 1999). 
ERK-mediated phosphorylation enhances its association with N-WASP, leading to increased 
actin polymerization mediated by the Arp2/3 complex (Martinez-Quiles et al., 2004) as shown in 
Figure 1.12 (B). Protein kinase D (PKD) phosphorylates CTTN on S298, which appears to 
increase cell migration owing to activation of the Arp2/3 complex (Eiseler et al., 2010). In 
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addition to S298, PKD phosphorylates CTTN at S348 in breast cancer cells, but the role of this 
second phosphorylation site is unclear (De Kimpe et al., 2009). 
 Another mechanism to affect cell motility is by affecting cell adhesion; CTTN null cells 
have more prominent focal adhesion (Lai, Szczodrak et al. 2009) thus affecting cell spreading, 
which is an adhesion-dependent process. CTTN regulation of adhesion is a likely mechanism to 
regulate motility (Owen, Pixley et al. 2007). Hyper phosphorylation of CTTN causes increased 
cell migration. Interestingly, it appears that tyrosine and serine phosphorylation can occur 
simultaneously, suggesting that it can integrate signals from diverse upstream signaling cascades 
(Kelley et al., 2010b; Kelley et al., 2011) to mediate its action. 
 Expression of CTTN mRNA in bladder cancer is associated with metastasis and poor 
prognosis, implicating its role in invasiveness of cancer cells. Overexpression of this protein has 
been observed in 15% of primary metastatic breast carcinomas and in nearly 30% of head and 
neck squamous cell carcinomas (Akervall, Jin et al. 1995, Buday and Downward 2007). Increased 
expression of CTTN has been linked to invasive cancers such as melanoma, colorectal, and 
glioblastoma making it an important biomarker for invasive cancers (Hirakawa, Shibata et al. 
2009, Kirkbride, Sung et al. 2011).  
1.6 Akt signaling  
The serine threonine kinase Akt is the central cell survival signaling node in cancer. Aberrant loss 
or gain of function of Akt leads to various pathological conditions (Bellacosa, Testa et al. 1991). 
Activation of receptor tyrosine kinases triggers PI3K signaling. This is generally mediated by the 
adaptor protein IRS1, which binds and activates PI3K. Activated PI3K converts PIP2 to PIP3, 
which then causes translocation of Akt from the cytoplasm to the plasma membrane. Akt at the 
plasma membrane comes in close proximity to PDK1 and mTORC2 which then phosphorylate it 
at Thr 308 and Ser 473 respectively (Manning and Cantley 2007). Akt signaling is inhibited by 
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phosphatases as PTEN and PHLPP1/2 (Gao, Furnari et al. 2005). The PI3K/Akt signaling has 
been illustrated in detail in Figure 1.13. 
 Akt has three isoforms: Akt1, Akt2 and Akt3. These isoforms are highly homologous 
structurally. They each have four basic domains: PH domain, linker region, catalytic domain and 
regulatory domain. The PH domain, catalytic domain, and regulatory domain share a high level of 
homology amongst the isoforms, however the linker region varies in the three isoforms (Clark 
and Toker 2014). Phenotypes of individual Akt isoform knockouts suggest that these isoforms 
have non-redundant functions (Cho, Thorvaldsen et al. 2001, Garofalo, Orena et al. 2003, 
Dummler and Hemmings 2007). Although the role of Akt isoforms in cell survival and metastasis 
of colorectal cancer cells has been described in detail in the next chapter, we will discuss some of 
the major downstream substrates of Akt. Some of the Akt substrates are known to control more 
than one function. 
Akt plays a critical role in promoting cell survival by inhibiting pro-apoptotic proteins. It 
negatively regulates Bcl-2 family proteins. It phosphorylates BAD at Ser 136, thus leading to an 
increase in its binding with 14-3-3 and increased cell survival (Datta, Katsov et al. 2000). Akt is 
also known to inhibit BH3-only proteins by affecting the expression of FOXO and p53. Akt 
phosphorylates FOXO proteins thus inhibiting their function of promoting apoptosis, cell cycle 
arrest and metabolic processes (Tran, Brunet et al. 2003). Additionally, Akt phosphorylates GSK3 
thereby activating it   which in turn are known to inhibits the pro-survival Bcl-2 fmaily member 
MCL-1 (Maurer, Charvet et al. 2006). Pro-caspase-9 is directly phosphorylated by Akt, leading to 
a reduction in its protease activity (Cardone, Roy et al. 1998). Akt also exerts cell survival effects 
through cross talk with other pathways such as NF-kappa B pathway and the JNK/p38 pathway 
(Ozes, Mayo et al. 1999, Kim, Khursigara et al. 2001). 
 The mTOR1 complex is activated by Akt. mTORC1 regulates translation initiation and 
ribosome biogenesis, thus affecting the growth of the cells (Wullschleger, Loewith et al. 2006). 
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Activation of Akt is known to affect the downstream targets of the mTORC1 complex, such as 
S6K1 and eukaryotic initiation factor 4E (elF4E) binding protein (Sekulic, Hudson et al. 2000). 
Akt is also known to phosphorylate and inhibit the tumor suppressor tuberous sclerosis complex 2 
(TSC2), one of the negative regulators of mTORC1 signaling (Manning, Tee et al. 2002). Akt can 
also stimulate cell proliferation by regulating the cell cycle. It phosphorylates p27, a cyclin-
dependent inhibitor thus leading to increased binding to 14-3-3, which then sequesters p27 in the 
nucleus, thereby reducing its cell cycle inhibitory effects (Medema, Kops et al. 2000). Similarly 
Akt is also known to inhibit p21, thus leading to increased progression of cell cycle (Heron-
Milhavet, Franckhauser et al. 2006). Akt also regulates cyclin D, and cyclin E, thus affecting the 
G1-S phase of cell cycle transition (Yeh, Cunningham et al. 2004). 
PI3K/Akt signaling also leads to increased vasodilation, vascular modeling and 
angiogenesis by increasing the expression of endothelial nitric oxide synthase (eNOS) 
(Dimmeler, Fleming et al. 1999). Additionally, Akt signaling increases the production of 
HIF1alpha through mTORC1 translation. Activation of HIF1alpha increases the expression of 
VEGF and other angiogenic factors, leading to increased vascular growth (Gordan and Simon 
2007).  
Recently, a role for Akt in cell migration and invasion has also been determined. Akt 
increases epithelial to mesenchymal transition (EMT) thus leading to increased metastasis (Irie, 
Pearline et al. 2005). Additionally, Akt also affects the stability of nuclear factor of activated T 
cells (NFAT), thus regulating metastasis (Yoeli-Lerner, Yiu et al. 2005). It has been identified 
recently that the 3 isoforms of Akt affect cell migration in an opposing way, in which Akt1 
inhibits migration but Akt2 is known to enhance the metastatic phenotype (Arboleda, Lyons et al. 
2003). 
Understanding the downstream signaling pathways of Akt help us to understand the 
mechanism of how Akt affects various cell biological processes. We have gained a better 
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understanding of Akt functions by knockout, knockdown or by pharmacological inhibition of Akt 
or specific Akt isoforms, however still more needs to be done to confirm which isoform of Akt 
plays the most important role. The information provided in the following chapters of this 
dissertation helps us to better answer this question. 
1.7 Figures 
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Figure 1.1: Different stages of colorectal cancer from stage 1 to stage 5. Stage 0 is marked with 
the presence of a polyp, which then grows progressively to form a tumor, which in turn undergoes 
metastasis and migrates to distant sites. This figure has been adapted from Bailey (2014) “The 
role of EPA in chemoprevention of colorectal cancer” with permission. 
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Figure 1.2: Progression model representing the genes and growth factors that are altered in colon 
cancer. The genes responsible for transition from final stage of colon cancer to metastasis 
(depicted by question mark) are still unknown. This figure has been adapted from Markowitz and 
Bertangnolli (2009) N Eng J Med 2009: 361:2449-60 with permission. 
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Figure 1.3: Illustrates the inefficiency of metastasis. Most of the steps of metastasis are 
inefficient, with metastatic colonization being the rate-limiting step. This figure depicts the 
fraction of cells that have died along the metastatic cascade. There is about a 99% attrition of 
cells in the process of formation of metastatic spots. This figure has been adapted from Valastyan 
and Weinberg (2011) Cell 2011: 147 (2): 275-292 with permission. 
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Figure 1.4: Illustration of the various steps of metastasis and some of the important signaling 
molecules that help cells to undergo metastasis. This figure has been adapted from Valastyan and 
Weinberg (2011) Cell 2011: 147 (2): 275-292 with permission.  
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Figure 1.5: Representation of the domain structure of IAP family members. This figure has been 
adapted from Ribe and Troy (2008) Biochemical journal 2008: 415 (2) 156-182 with permission. 
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Figure 1.6: Depiction of XIAP signaling to regulate cell death. The BIR domains of XIAP inhibit 
the caspases leading to increase in apoptosis. Ubiquitination of XIAP leads to a reduction in the 
expression of XIAP and an increase in the expression of AIF. This figure has been adapted from 
Fillipovich and Marsh (2010) Blood 2010:116 (8) : 3398-3408 with permission. 
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Figure 1.7: Illustrates the functions of survivin. This IAP family member regulates mitosis 
through CPCs. It forms a complex with XIAP thus leading to inhibition of apoptosis; 
additionally, via alpha 5 integrin, survivin also regulates cell motility. This figure has been 
adapted from McKenzie and Grossman (2012) Anticancer Res. (2012) 32 (2) : 397-404 with 
permission. 
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Figure 1.7: 
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Figure 1.8: Represents that survivin can lead to both caspase-dependent and caspase-independent 
cell death. Caspase-independent cell death is mediated via AIF. This figure has been adapted 
from Grossman (2004) Oncogene 2004: 23 (1): 39-48 with permission. 
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Figure1.8: 
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Figure 1.9: Domain structure of Apoptosis Inducing Factor.  This figure has been adapted from 
Mader and Bleackely 2009 Mol Cancer Res (2009): 7 (5): 689-702 with permission. 
 
Figure 1.10: Represents the mechanism of action of Apoptosis Inducing Factor. Stress causes the 
release of AIF from the mitochondria to the nucleus, where it leads to DNA fragmentation and 
then leading to cell death. This figure has been adapted from Mader and Bleackely 2009 Mol 
Cancer Res (2009): 7 (5): 689-702 with permission. 
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Figure 1.9: 
 
 
 
 
Figure 1.10: 
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Figure 1.11: Domain structure of MTSS1. It has an IMD domain, a serine-rich domain and 
proline-rich domain. The figure also depicts the binding partners of MTSS1. This figure has been 
adapted from Machesky and Johnston (2007) J Mol Med (2007): 85: 569-576 with permission. 
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45 
 
Figure 1.12: (A) Domain structure and the binding partners of Cortactin. CTTN has a NTA 
domain at the N-terminus and a SH3 binding domain at the C-terminus. There are binding sites 
for several kinases which then lead to phosphorylation and activation of CTTN. (B) CTTN binds 
to Arp2/3 comple, leading to actin polymerization. This figure has been adapted from Binker and 
Kapus (2006) Physiology 2006: 21: 352-361 with permission. 
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Figure 1.12: 
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Figure 1.13: PI3K/Akt signaling. This figure has been adapted from Cheaib and Leary (2015) 
Chin J Cancer 2015 : 34 (1) : 4-16 with permission. 
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Figure 1.13: 
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2. Cell Survival and Metastasis Regulation by Akt Signalling in Colorectal Cancer 
2.1 Abstract 
Dissemination of cancer cells to distant organ sites is the leading cause of death due to treatment 
failure in different types of cancer. Mehlen and Puisieux have reviewed the importance of the 
development of inappropriate cell survival signalling for various steps in the metastatic process 
and have noted the particular importance of aberrant cell survival to successful colonization at the 
metastatic site. Therefore, the understanding of mechanisms that govern cell survival fate of these 
metastatic cells could lead to the understanding of a new paradigm for control of metastatic 
potential and could provide the basis for developing novel strategies for the treatment of 
metastases. Numerous studies have documented the widespread role of Akt in cell survival and 
metastasis in colorectal cancer, as well as many other types of cancer. Akt acts as a key signalling 
node that bridges the link between oncogenic receptors to many essential pro-survival cellular 
functions, and is perhaps the most commonly activated signalling pathway in human cancer. In 
recent years, Akt2 and Akt3 have emerged as significant contributors to malignancy alongside the 
well-characterized Akt1 isoform, with distinct non-overlapping functions. This chapter is aimed 
at gaining a better understanding of the Akt-driven cell survival mechanisms that contribute to 
cancer progression and metastasis and the pharmacological inhibitors in clinical trials designed to 
counter the Akt-driven cell survival responses in cancer.  
2.2 Introduction 
Colorectal cancer (CRC) is one of the most common malignancies with high incidence rates 
globally (Stein, Walther et al. 2009). It develops due to various genetic, epigenetic and 
environmental factors. The stage I CRC is localized to the mucosal and submucosal layers of the 
colon wall. Surgery and multimodal treatments are the preferred strategies following early stage 
diagnosis of CRC with a 5-year survival rate of approximately 100%. This rate in 5-year survival 
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is significantly decreased during stage III CRC which is characterized by lymph node metastasis 
(Johnson, Gulhati et al. 2010). However, metastasis to distant organ sites (stage IV) is the most 
frequent cause of cancer-related deaths with a 5-year survival rate of <5% (Christofori 2006, 
Stein and Schlag 2007). CRCs progress slowly to an invasive stage, but the progression from 
invasive carcinoma to metastatic phase occurs rapidly (Nguyen, Bos et al. 2009). The 
disseminating CRC cells acquire enhanced cell survival capabilities to counteract apoptosis 
initiated by the multi-step metastatic cascade including anoikis (Weigelt, Peterse et al. 2005), 
migration through the basement membrane and intravasation into the blood and/or lymphatic 
vessels. The CRC cells develop the ability to proliferate and colonize secondary organ sites with 
unrelated microenvironments (Weigelt, Peterse et al. 2005). There has been limited success in the 
early identification of patients at high risk for developing metastasis through the tissue-based 
biomarkers currently available for such purposes (Vansant, Johnson et al. 1992, Duffy, van Dalen 
et al. 2007). The mechanisms involved in regulating the early stages of the metastatic cascade that 
are crucial for diagnosis are currently not fully understood (Fearon and Vogelstein 1990, 
Bernards and Weinberg 2002, Vogelstein and Kinzler 2004, Takayama, Miyanishi et al. 2006). In 
recent years, several aberrant cell survival mechanisms have been linked to successful metastatic 
colonization (Mehlen and Puisieux 2006) including the deregulation of pro-survival Bcl-2 family 
proteins (Cory and Adams 2002), inhibitor-of-apoptosis (IAP) family proteins (Srinivasula and 
Ashwell 2008) and the PI3K/AKT signalling. The Bcl-2 family members are either pro-apoptotic 
or anti-apoptotic in nature (Youle and Strasser 2008). The pro-apoptotic proteins such as BID, 
BAX and BAK translocate in the mitochondria leading to caspase activation thus leading to cell 
death. The Bcl-2 family members have a BH3 domain that inhibits the anti-apoptotic members of 
the Bcl-2 family thus leading to apoptosis. Bcl-XL protein inhibits the activity of BAX and BAK 
by binding to them and inhibiting apoptosis (Grad, Zeng et al. 2000). BAX and BAK are 
responsible for caspase activation thus downregulating cell survival. Several lines of evidence 
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have implicated the role of Bcl-2 overexpression in promoting cell survival and metastasis (Del 
Bufalo, Biroccio et al. 1997, Pinkas, Martin et al. 2004). However, contrasting reports from 
Subhawong et al. concluded that Bcl-2 is infrequently upregulated in metastatic breast carcinoma 
and hormone therapy resistance may lead to downregulation of Bcl-2 (Subhawong, Nassar et al. 
2010). IAPs are also responsible for regulating apoptosis by inhibiting caspases. Some IAPs have 
been shown to inhibit caspases by inhibiting their enzyme activity and/or by targeting them for 
proteasomal degradation (Vaux and Silke 2005). Caspases 3,7 and 9 bind to the BIR (Baculoviral 
IAP repeat) domains of IAPs leading to their inhibition and increased cell survival (Deveraux, 
Leo et al. 1999). Recently, the Altieri laboratory has shown that IAP family members survivin 
and XIAP are playing an essential role in metastasis (Mehrotra, Languino et al. 2010).  
Overexpression of survivin has been observed in colorectal tumorigenesis. Survivin plays a role 
in the progression of adenomas from the mild dysplasia to the more advanced highly dysplastic 
lesions (Kawasaki, Toyoda et al. 2001). Several survivin inhibitors are currently in phase I or II 
clinical trials in solid tumors and non-Hodgkins lymphoma (Kelly, Lopez-Chavez et al. 2011). 
YM155 (1-(2-Methoxyethyl)-2-methyl-4, 9-dioxo-3- (pyrazin-2-ylmethyl)-4,9-ihydro-H-naphtho 
[2,3]-dimidazolium bromide) (Astellas Pharma Inc) is a transcriptional inhibitor of survivin. It 
has been demonstrated to have a potent anti-tumor activity and has been used as a radio-
sensitizing agent to potentiate the anti-cancer functions of various chemotherapeutic agents 
(Nakahara, Kita et al. 2007, Iwasa, Okamoto et al. 2008, Kelly, Lopez-Chavez et al. 2011). The 
phosphoinositide 3‑ kinase (PI3K) – Akt signalling pathway, which transmits anti-apoptotic 
signals, is involved in a significant fraction of human tumors promoting cancer cell growth, 
metabolism, survival and has been implicated in EMT, angiogenesis and metastasis (see reference 
(Fresno Vara, Casado et al. 2004, Altomare and Testa 2005, Hennessy, Smith et al. 2005, 
Manning and Cantley 2007, Sheng, Qiao et al. 2009) for extensive on PI3K/Akt signalling in 
cancer. A better understanding of the molecular signalling pathways involved in the process of 
53 
 
metastasis will help in effectively targeting these aggressive cancer cells using novel therapeutic 
strategies.  
In this chapter, we have focused on the emerging roles of Akt isoforms in various types 
of cancer, including colorectal, breast, lung and pancreatic cancer, and have discussed the 
TGFβ/PKA metastatic suppressor pathway that negatively regulates Akt-driven aberrant cell 
survival mechanisms that contribute to metastatic progression in CRC. Additionally, we have 
provided updates on various Akt inhibitors that are in clinical trials.   
2.3 PI3K – Akt signalling in cancer 
The PI3K signalling pathway is a major link between oncogenic receptors and downstream pro-
survival molecules and is one of the most frequently activated signalling pathways in human 
cancers (Vivanco and Sawyers 2002, Bader, Kang et al. 2005, Engelman, Luo et al. 2006). It is 
known that multiple small GTPases that belong to Ras and Rho-kinase family of GTPases 
activate PI3K (Yang, Shin et al. 2012). It has also been shown that Rho GTPases are downstream 
activators of PI3K. These Rho GTPases amplify the PI3K activity by feedback mechanisms 
(Weiner, Neilsen et al. 2002).  The stimulation by growth factors leads to the activation of 
receptor tyrosine kinases (RTKs), that in turn recruits the class IA PI3Ks, consisting of p110α–
p85 subunits, to the membrane due to the direct protein-protein interaction between p85 and 
activated RTKs (for example, IGFR and EGFR). Alternatively, the p85 subunit can also interact 
with specific adaptor proteins, such as Insulin Receptor Substrate 1/2 (IRS1/2) associated with 
IGFR (Figure 2.1). 
The activated p110α catalytic subunit converts phosphatidylinositol4, 5bis phosphate (PIP2) to 
phosphatidylinositol3, 4, 5trisphosphate (PIP3) at the membrane. The conversion of PIP2 to PIP3 
provides docking sites for pleckstrin homology (PH) domain-containing proteins, including 
3phosphoinositide-dependent protein kinase 1 (PDPK1) and serine–threonine protein kinase Akt 
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(also known as protein kinase B). PDPK1 phosphorylates Akt at Ser473 and PDK2 
phosphorylates Akt at Thr308. The dual activation of Akt at Ser473 and Thr308 phosphorylation 
sites elicits a broad range of downstream signalling events as shown in Figure 2.2. The tumor 
suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN) inhibits PI3K 
activation and downstream signalling by dephosphorylating PIP3 (Vivanco, Rohle et al. 2010). 
Deletion, mutation and hypermethylation of PTEN are observed in various cancer conditions thus 
resulting in elevated Akt activity (Georgescu 2010). A study in rhabdomyosarcoma cells has 
shown that PTEN is responsible for dephosphorylation specifically at the Ser473 site of Akt (Wan 
and Helman 2003). PHLPP (PH domain leucine-rich repeat protein phosphatase) specifically 
dephosphorylates Akt at Ser473 thus attenuating Akt signalling (Gao, Furnari et al. 2005). It has 
two isoforms PHLPP1 and PHLPP2, which are very specific in their mode of action.  PHLPP1 
and PHLPP2 specifically dephosphorylate Akt2 and Akt1 respectively (Nitsche, Edderkaoui et al. 
2012). The expression of these phosphatases decreases in many cancer types, including colon 
cancer and glioblastoma, thus resulting in increased Akt activation and its downstream oncogenic 
signalling pathways (Liu, Weiss et al. 2009). PP2A (protein phosphatase 2A) is a serine threonine 
phosphatase, which is ubiquitously expressed in the tissues. It regulates Akt by inhibiting its 
phosphorylation at Thr308 (Kuo, Huang et al. 2008). It is a tumor suppressor gene since its 
inhibition by okadaic acid results in increase in cell survival thus increasing tumor growth 
(Suganuma, Fujiki et al. 1988). It has been shown that there is an increase in the expression of 
PP2A inhibitors in various cancer conditions (Li, Chen et al.). We have recently demonstrated a 
novel pathway of cell death in colon cancer, mediated by PP2A where it inhibits the 
phosphorylation of Akt, thus disrupting the XIAP/Survivin complex resulting in increased cell 
death (Chowdhury, Howell et al. 2011). The overall mechanism of cell death mediated by this 
pathway has been explained in detail in the later part of the chapter.  
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 Genomic analyses have revealed that many components of the PI3K/Akt pathway are 
frequently mutated or altered in common human cancers underscoring the importance of this 
pathway in cancer (Liu, Cheng et al. 2009). The genes encoding the PI3K catalytic subunits 
PI3KCA, PI3KCB, regulatory subunit of PI3K, p85, PDK1, PTEN undergo loss of function or 
overexpression in various tumor conditions thus leading to cancer. 
2.4 Distinct roles for Akt isoforms in cancer progression and metastasis 
Akt is an evolutionarily conserved serine/threonine kinase consisting of 3 members, i.e., Akt1 
(PKBα), Akt2 (PKBβ) and Akt3 (PKBγ). The Akt isoforms have distinct non-redundant 
functional characteristics despite sharing a high level of structural homology and similar 
mechanisms of activation (Cantley 2002, Chin and Toker 2009). The Akt isoforms are 
ubiquitously expressed in all cell types and tissues. However, the pattern of Akt3 expression is 
restricted (Toker and Yoeli-Lerner 2006). Akt1 is widely expressed in brain, heart and lungs; 
however, Akt2 is mostly expressed in skeletal muscles(Suganuma, Fujiki et al. 1988, Brodbeck, 
Cron et al. 1999). Akt3 is expressed in brain, kidney and embryonic heart (Nakatani, Thompson 
et al. 1999). These Akt isoforms also show difference in their cellular localization. Akt1 is known 
to localize in the cytoplasm; Akt2 localizes in the nucleus, cytoplasm and mitochondria 
(Andjelkovic, Alessi et al. 1997, Calera, Martinez et al. 1998, Kupriyanova and Kandror 1999, 
Cantley 2002, Borgatti, Martelli et al. 2003). However, Akt3 is known to localize in the nuclear 
membrane (Kupriyanova and Kandror 1999, Yang, Tschopp et al. 2003). Knockdown of 
individual Akt isoforms does not affect the localization pattern of other Akt isoforms and also has 
been shown to have no compensatory effects on the level of other isoforms (Santi and Lee 2009). 
Numerous studies have been done in genetically engineered mice deficient for Akt1, Akt2 or 
Akt3 to confirm that these isoforms have different physiological functions (Peng, Xu et al. 2003). 
Variable phenotypic differences are observed following the genetic inactivation and/or removal 
of the Akt isoforms. Akt1 knockout mice exhibit retardation in growth and an increase in 
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perinatal lethality (Okano, Gaslightwala et al. 2000, Yang, Tschopp et al. 2003). Removal of 
Akt2 in mice results in insulin resistance and diabetes mellitus (Cho, Mu et al. 2001) whereas 
Akt3 knockout results in reduction in brain size and development (Easton, Cho et al. 2005). 
Double knockout mice harboring deficiency of both Akt1 and Akt2 isoforms die immediately 
after birth (Dummler and Hemmings 2007). However there are no studies available related to 
double knockdown of Akt3 in combination with Akt1 or Akt2. 
Akt isoforms are aberrantly expressed in tumor conditions but these isoforms have tumor 
specific expression. Akt1 amplification is commonly observed in gastric cancer cells and 
knockdown of Akt1 increases the sensitivity of gastric cancer cells to chemotherapy as 
determined by treatment with cisplatin. Akt1 knockdown in gastric cancer cells increases the 
expression of BAX and reduces the expression of Bcl-2 thus increasing cell death in vitro and in 
vivo (Zhou, Fu et al. 2012). Akt2 is abnormally expressed in breast, ovarian and colon cancers 
(Suganuma, Fujiki et al. 1988, Chau and Ashcroft 2004, Easton, Cho et al. 2005). Akt3 undergoes 
amplification in breast and prostate cancer (Nakatani, Thompson et al. 1999, Bacus, Altomare et 
al. 2002, Zhou, Fu et al. 2012). In the following section, we have discussed the role of Akt 
isoforms in colorectal, breast, lung and pancreatic cancer. Numerous cross-talk and feedback 
mechanisms regulate PI3K/Akt signalling. Recently, Heron-Milhanet et al. has extensively 
reviewed the differential action of Akt1 and Akt2 in cancer and pointed towards the significance 
of targeting isoform-specific downstream events for the development of effective anti-cancer 
therapies involving Akt kinases (Heron-Milhavet, Khouya et al. 2011).  
2.4.1 Colorectal cancer 
Several studies have documented the inhibition of apoptosis as a critical event in the development 
of colorectal malignancies. The overexpression of anti-apoptotic proteins or the inactivation of 
pro-apoptotic proteins is a common event in colorectal carcinogenesis that is usually dependent 
on the genetic background of the tumor (Roy, Olusola et al. 2002). Sporadic colon cancers are 
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associated with inhibition of apoptosis in association with the loss of function of tumor 
suppressor adenomatous polyposis coli (APC), along with overexpression of anti-apoptotic Bcl-2 
proteins (Chung 2000). However, CRC that originates due to DNA mismatch repair deficiency 
resulting in microsatellite instability (MSI) are usually associated with inactivating mutations of 
the pro-apoptotic BAX protein. About 6-15% of sporadic (non-hereditary) colon cancers are MSI 
positive, while the majority of tumors from patients with hereditary non-polyposis colorectal 
cancer (HNPCC) are MSI positive (Lynch and Smyrk 1998). Roy et al. demonstrated for the first 
time that Akt overexpression is an early event during sporadic colon carcinogenesis (Roy, 
Olusola et al. 2002). This increased Akt expression was specific to sporadic colon carcinogenesis 
as opposed to the human MSI-high tumors represented by a series of HNPCC tumors. It was 
shown that 57% of all colorectal cancer specimens tested were positively immunostained for Akt. 
However, normal colonic mucosa and hyperplastic polyps expressed negligible levels of Akt. Roy 
et al. also reported for the first time that 57% of all adenomas overexpressed Akt indicating that 
overexpression of Akt is an early event in colon carcinogenesis. Interestingly, th Akt2 isoform 
was indicated as a predominant player in colon carcinogenesis. Additionally, Akt phosphorylation 
at Ser473 was detected in colon carcinomas but not in normal epithelium. This study concluded 
that Akt overexpression (especially Akt2) may be important in the early inhibition of apoptosis 
during colon carcinogenesis (Roy, Olusola et al. 2002).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
The independent roles for Akt isoforms in regulating malignant progression in colorectal and 
breast cancer was recently reported by Yoeli-Lerner etal. (Toker and Yoeli-Lerner 2006, Yoeli-
Lerner and Toker 2006) demonstrating that Akt1 overexpression inhibits the transcriptional 
activity of NFAT (nuclear factor of activated T cells) thus resulting in the blockade of invasion 
and migration. It is postulated that NFAT is targeted through Akt1-HDM2 (Human analogue of 
MDM2) pathway. HDM2 is an E3 ubiquitin ligase, that ubiquitinates its target proteins, such as 
NFAT, for proteasomal degradation. It was observed that NFAT degradation was rescued in the 
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presence of HDM2 siRNA (Yoeli-Lerner, Yiu et al. 2005). Feng et al. has shown that Akt1 
stabilizes MDM2 by phosphorylating Ser166 and Ser188 residues, thus inhibiting its self-
ubiquitination and increasing its stability. (Feng, Tamaskovic et al. 2004). In contrast, Akt2 
overexpression up-regulates β1-integrin (a component of collagen IV- binding receptor; referred 
to here as β1) expression both in vivo and in vitro (Arboleda, Lyons et al. 2003). Increased β1 
expression is responsible for increased metastasis (Coffer and Woodgett 1992, Morini, Mottolese 
et al. 2000). This capability of Akt2 has been attributed to the fact that Akt2, in addition to 
regulating cell migration and invasion, also inhibits apoptosis. Thus Akt1 inhibits metastasis and 
invasion by degrading NFAT, however, Akt2 up-regulates β1-integrin expression resulting in 
increased cell migration and invasion, depicting their contradictory roles in cancer. Amplification 
and overexpression of Akt2 has been shown to play a critical role in CRC metastatic colonization 
(Rychahou, Kang et al. 2008). Akt2 is a proto-oncogene, and is highly expressed in metastatic 
colon carcinoma as compared to primary colon cancer (Yuan, Sun et al. 2000). Genetic 
inactivation of Akt2 has been shown to result in reduced ability of colon carcinoma cells to 
metastasize thus confirming that Akt2 is required for the establishment of colon cancer metastasis 
(Ericson, Gan et al. 2010).However, the exact mechanism of Akt2-driven metastasis is poorly 
understood. Genetic inactivation of Akt1 and Akt2 results in reduction in clonal growth of colon 
cancer cells in vitro, but this reduction was much more significant when the cells were cultured in 
media lacking growth factors (Ericson, Gan et al. 2010).This led to the conclusion that tumor 
microenvironment plays a significant role in regulating the effects of gene inactivation 
(Vogelstein and Kinzler 2004). Inactivation of Akt1 and Akt2 also results in reduced metastasis 
to liver and reduced tumor burden (Ericson, Gan et al. 2010). Activated Akt regulates the 
expression of Bcl-2 and FAK (focal adhesion kinase) proteins mediating CRC metastasis (Lee, 
Kim et al. 2011, Wang and Basson 2011). In response to stress, Akt1 binds directly to FAK thus 
phosphorylating it at three serine residues (Ser 517, 601, 695) (Berwick, Hers et al. 2002). 
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Phosphorylation of the 3 serine residues in turn phosphorylate the tyrosine residue (Tyr397) thus 
activating it. This in turn induces cell adhesion by increasing the binding of integrins to matrix 
thus leading to increased metastasis (Thamilselvan, Craig et al. 2007). In addition to the 
overexpression of Akt isoforms in different cancer types, Akt phosphorylation in human CRCs 
has been shown to correlate with cell proliferation and apoptosis inhibition, and has also been 
demonstrated to increase with advancement of CRC (Itoh, Semba et al. 2002, Khaleghpour, Li et 
al. 2004). It is well documented that mTOR (mammalian target of rapamycin), which promotes 
growth, protein translation and metabolism is regulated by Akt kinase. The Sabatini laboratory 
has made the seminal discovery that mTOR is a direct substrate of Akt and identified Ser2448 
residue as the Akt phosphorylation site on mTOR (Guertin and Sabatini 2007). The Evers 
laboratory has recently demonstrated that the mTOR1/mTOR2 proteins Raptor and Rictor are 
highly expressed in CRC tissues (Gulhati, Cai et al. 2009). Importantly, Rictor expression was 
correlated with pAKT Ser473 expression in CRCs derived from same patient. Johnson et al. 
showed that p85α, Akt1, Akt2 and pmTOR Ser2448 were all overexpressed in CRC compared to 
control and additionally reported that the expression of Akt1 and Akt2 was more pronounced in 
the left-sided CRCs compared to the right-sided CRCs (Johnson, Gulhati et al. 2010). 
The molecular networks and pathways affected by the predicted mRNA targets of Akt2 in 
context of CRC metastasis signalling were depicted using the Ingenuity Pathway Analysis (IPA) 
tool and are shown in Figure 2.3. The IPA analysis of Akt2 revealed that Akt2 targets multiple 
genes frequently deregulated in cancer. Some of these target genes have been identified 
previously as directs targets for Akt2 and have been implicated in invasion and metastasis 
(including the MMP-9, EGF and SRC). Additionally, the predicted mRNA targets of Akt2 also 
included apoptosis regulators such as BAX, JNK/p38, TP53, NF-κB and Caspase3. Yuan et.al. 
demonstrated that Akt2 altered the cisplatin-induced apoptosis in ovarian cancer cells by 
regulating the ASK1/JNK/p38 pathway (Yuan, Feldman et al. 2003). ASK1 (apoptosis signal-
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regulating kinase 1) is a member of the mitogen-activated protein kinase kinase kinase family that 
mediates cell death in response to various stresses including chemotherapeutic drugs such as 
cisplatin and paclitaxel (Yuan, Feldman et al. 2003). Stimulation of JNK/p38 activity has also 
been shown to be critical for cisplatin-induced apoptosis in certain cancer cell types. It was shown 
that AKT2 interacts with and phosphorylates ASK1 (apoptosis signal-regulating kinase 1) at Ser-
83 residue. This leads to the inhibition of ASK1 kinase activity, blockade of JNK/p38 activation 
and activation of BAX. This work provided a new highlight on the role of Akt2 in regulating the 
ASK1/JNK/p38/BAX pathway and provided a new mechanistic insight into the anti-apoptotic 
effects of Akt2 (Yuan, Feldman et al. 2003).  
2.4.2 Breast cancer 
In breast cancer, Akt upregulates matrix metalloproteases (MMPs)-mediated matrix degradation 
resulting in increased metastasis (Jung, Park et al. 2010). In estrogen receptor-positive (ER+) 
breast cancer cells, Akt2 activation is triggered by ER-α. Akt2 expression is higher in Her2/neu 
breast cancer compared to Her2 negative tumors with increased resistance to stress-mediated cell 
death and less susceptibility to chemotherapeutics (Bacus, Altomare et al. 2002). Due to the 
intrinsic tyrosine kinase activity of Her2/neu, the receptor undergoes dimerization and activation, 
even in the absence of ligand, which in turn activates PI3K (Newby, Johnston et al. 1997, Zhou, 
Hu et al. 2000). Akt1 is upregulated in breast cancer samples although there is no significant 
correlation between Her2/neu and Akt1 expression (Bacus, Altomare et al. 2002). In contrast, 
ER-β causes reduction in Akt signalling in ERα positive breast cancer cells, thus affecting cell 
proliferation and survival along with increasing the sensitivity of cells for tamoxifen (ER 
antagonist) treatment (Lindberg, Helguero et al. 2011). Increased expression of Akt3 has been 
observed in hormone-unresponsive breast tumors thus contributing to their aggressive and 
metastatic phenotype. Chung et al.(Chung, Yao et al. 2012) showed that N-cadherin specifically 
suppressed Akt3 activity and promoted tumor cell migration in breast cancer cells, however, N-
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cadherin had no effects on Akt1 and Akt2 isoforms, thereby associating Akt3 with epithelial-to-
mesenchymal transition (EMT), a crucial step in metastasis. These studies were further confirmed 
by knockdown of Akt3, which resulted in increased cell motility with no effect on cell 
proliferation (Chung, Yao et al. 2012). The mechanism of reduction in Akt3 activity by N-
cadherin is yet to be determined; however, it was observed that the expression of Akt3 mRNA 
was affected by N-cadherin but the protein expression remains unchanged, thus the transcription 
of Akt3 is reduced by N-cadherin.  
2.4.3 Lung cancer 
Grabinski et al. reported a high activity of Akt3 isoform in lung cancer cells that regulates the 
expression of cyclin D3, thus promoting G1-S transition of cell cycle (Cristiano, Chan et al. 
2006). Akt3 siRNA knockdown reduced proliferation, survival and migration of lung cancer 
cells. In contrast, Akt1 siRNA knockdown resulted in a reduction in MEK/ERK1/2 activity 
(Rommel, Clarke et al. 1999) and IkB protein expression leading to cell death (Romashkova and 
Makarov 1999).  However, reduction in Akt2 expression induces MCL-1 cleavage cell death 
through mitochondrial membrane potential loss and release of cytochrome c in the cytosol (Lee, 
Kim et al. 2011). Akt1 undergoes a mutation at the 17
th
 position (Glutamic acid is mutated to 
Lysine E17K) and this mutation is generally observed in breast, colon and ovarian cancers 
(Carpten, Faber et al. 2007). Recently, it was reported that non-small cell lung carcinoma 
(NSCLC) patients also possess a E17K mutation in Akt1 although the frequency is much less 
(Sung, Park et al. 2012).  Kim et al. has confirmed that Akt1 polymorphism might be used as a 
prognostic marker for NSCLS (Kim, Kim et al. 2006). However, Sung et al reported that 
polymorphism in Akt2 and Akt3 is not associated with NSCLC (Sung, Han et al. 2008).  
2.4.4 Pancreatic cancer 
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Akt activation due to mutation of the Kras or PTEN pathway is a potent survival signal in 
pancreatic cancer cell lines (Stambolic, Suzuki et al. 1998) and correlates with the aggressiveness 
of tumor. Specifically, Akt2 is amplified in 60% of pancreatic cancer (Schlieman, Fahy et al. 
2003) and has been associated with increased growth and invasiveness in human ductal 
pancreatic cancer. There is a significant increase in the expression of Akt2 and pAkt (p<0.01) in 
pancreatic ductal adenocarcinoma (PDAC) (Yamamoto, Tomita et al. 2004). Akt2 is considered a 
prognostic marker for PDAC. Inhibition of Akt2 signaling by PI3K inhibitor results in the 
reduction in growth of pancreatic cancer cells in vitro and in vivo, by induction of apoptosis. 
Therefore Akt2 can be an important therapeutic target for treatment of pancreatic cancer (Ng, 
Tsao et al. 2000). It has been reported that Akt isoforms show differential roles in pancreatic 
cancer. Whereas Akt2 is responsible for poor prognosis, Akt1 is associated with favorable 
prognosis of pancreatic cancer (Yamamoto, Tomita et al. 2004). As mentioned above PHLPPs are 
responsible for dephosphorylation of Akt thus inactivating it. Nitschie et al. studied the 
expression of PHLPP1 and PHLPP2 in pancreatic cancer and observed a reduction in the 
expression of these phosphatases in PDAC as compared to normal pancreas. It was also reported 
that increased expression of PHLPP1 results in reduction in tumor growth confirming that it is the 
loss of phosphorylation of Akt2 that causes reduced growth of cancer cells (Nitsche, Edderkaoui 
et al. 2012). 
2.5 TGFβ-Akt signalling crosstalk regulates aberrant cell survival in CRC metastasis 
TGFβ signalling plays a critical role in cell survival and metastasis. TGFβ inhibitory/tumor 
suppressor responses are decreased with increasing malignant progression and in advanced-
stages, TGFβ promotes invasion and metastasis. Substantial reports from our laboratory have 
established a loss or epigenetic silencing of TGFβ receptor expression in a wide range of cancer 
(Ammanamanchi, Freeman et al. 2003, Ammanamanchi and Brattain 2004, Huang, Zhao et al. 
2005, Chowdhury, Howell et al. 2011). The mechanisms of epigenetic loss of TGFβ receptors 
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and their therapeutic implications have been reviewed in detail (Chowdhury, Ammanamanchi et 
al. 2009). Recently, we have demonstrated that reconstitution of TGFβ receptor expression in 
CRC cell lines with attenuated TGFβ receptor signalling resulted in the inhibition of metastatic 
colonization from primary colon tumors to lungs and liver. Significantly, invasion at the primary 
colon tumor was not prevented indicating that the effect of receptor reconstitution was on the 
ability to form progressively growing metastatic deposits at liver and/or lungs rather than 
preventing the initial steps in metastasis (Chowdhury, Howell et al. 2011). It has been shown that 
TGFβ-mediated apoptosis can be inhibited by insulin in hepatocytes and that the PI3K/Akt 
pathway (which is activated by insulin stimulation) is involved in this protective effect conferred 
by insulin (Tanaka and Wands 1996, Chen, Su et al. 1998, Buenemann, Willy et al. 2001). 
Although additional signalling pathways might contribute to TGFβ-induced responses, Smads are 
the only direct effectors known to act as transcription factors and therefore represent the most 
direct mediators for the transmission of TGFβ signalling from the cell surface to the nucleus 
(Kretschmer, Moepert et al. 2003). In systemic screening for Akt-associated proteins, Smad3 was 
identified as a binding partner (Conery, Cao et al. 2004, Remy, Montmarquette et al. 2004). We 
have shown previously that endogenous cellular TGFβ signalling increases apoptosis during 
growth factor deprivation stress (GFDS) in CRC cells (Wang, Yang et al. 2008). Further, the loss 
of autocrine TGFβ in colon cancer cells with attenuated TGFβ signalling resulted in increased 
PI3K/Akt activation and survivin expression, as well as resistance to GFDS-induced apoptosis 
(Wang, Yang et al. 2008). Interestingly, poorly metastatic FET colon cancer cells transfected with 
the neomycin vector (designated FETNeo) were compared with the highly metastatic FETDNRII 
cells that have been stably transfected with a dominant negative RII construct to knock out TGFβ 
signalling (Ongchin, Sharratt et al. 2009). In Figure 2.4 (unpublished data), the upper panel shows 
that relatively little Smad3 binds to Akt when TGFβ signalling is intact or in the absence of 
GFDS (“0” time for FETDNRII). When stress as reflected by GFDS is initiated there is rapid 
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induction of complex formation. In Figure 2.4, the lower panel shows that when GFDS is initiated 
in TGFβ autocrine competent cells there is a rapid loss of survivin expression. In contrast, loss of 
autocrine activity and Smad3/Akt complex formation results in the induction of survivin 
expression. The linkage of this apoptotic mechanism in human colon cancer cell lines to 
repression of survivin expression may be of significance, because survivin overexpression is 
strongly associated with poor prognosis in colon cancer (Wang, Yang et al. 2008). Survivin/XIAP 
complexes that mediate caspase inhibition have been shown to be a key cell survival mechanism 
enabling metastasis process (Dohi, Xia et al. 2007, Mehrotra, Languino et al. 2010). The complex 
is critical for stabilization of XIAP to inhibit caspases. Survivin and XIAP are in separate 
mitochondrial compartments, but are released by mitochondria into the cytoplasm in response to 
stress (such as metastatic growth in a foreign microenvironment) to promote cell survival. We 
recently identified a novel TGFβ/PKA signalling transduceome by which TGFβ-mediated cyclic 
AMP-independent PKA activation leads to disruption and subsequent destabilization of the 
survivin/XIAP complex to enable cell death due to PP2A mediated inhibition of Akt 
phosphorylation of a stabilizing XIAP site (S87) and direct phosphorylation of survivin at S20 
(Figure 2.5). Moreover, we have shown that Akt phosphorylation was higher in the highly 
metastatic CRC cells with attenuated TGFβ receptor. However, reconstitution of TGFβ receptors 
in these CRC cells led to a reduction in Akt phosphorylation followed by a reduction in metastatic 
colonization (Simms, Rajput et al. 2012).  
2.6 Clinical advancement of Akt as a therapeutic target  
2.6.1 MK-2206 
MK-2206 is an orally active allosteric kinase inhibitor of Akt. The chemical name of MK-2206 is 
8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f]  [1,6]naphthyridin-3(2H)-one 
hydrochloride [1:1]. MK-2206 is a highly potent and selective Akt kinase inhibitor (Hirai, 
Sootome et al. 2010). MK-2206 binds to the pleckstrin homology (PH) domain of Akt and thus 
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inhibits its phosphorylation and translocation to the plasma membrane thus inactivating Akt. It is 
presently in phase II clinical trial in colon cancer and breast cancer. Hirai et al. (2010) have 
demonstrated similar levels of MK-2206-mediated inhibition of the enzymatic activity of 
different Akt isoforms using purified recombinant human Akt1 (IC50, 5 nmol/L) and Akt2 
enzyme (IC50, 12 nmol/L) and approximately 5-fold less effectiveness against human Akt3 (IC50, 
65 nmol/L) (Hirai, Sootome et al. 2010). The authors showed for the first time the effectiveness 
of MK-2206 as a sensitizing agent for use in combination with various chemotherapeutic agents 
including docetaxel, carboplatin, gemcitabine, 5-fluorouracil (5-FU), doxorubicin, camptothecin, 
and RTK inhibitors such as lapatinib and erlotinib (Hirai, Sootome et al. 2010). In recent years, 
MK-2206 is being used in combination with EGFR and IGFR inhibitors in leukemia, breast, 
colon cancer and malignant gliomas (Cheng, Zhang et al. 2012). A recent study showed that MK-
2206 has antitumor role in breast cancer in vivo, which was further augmented in the presence of 
paclitaxel (Sangai, Akcakanat et al. 2012). This combination of MK-2206 and paclitaxel is 
important since paclitaxel is used in the treatment of breast cancer. A report on nasopharyngeal 
carcinoma (NPC) reveals that MK-2206 inhibits growth of NPC cells by inhibiting Akt and 
mTOR signaling. MK-2206 treatment results in reduction in survival of pediatric cancer cell lines 
in vitro and in vivo (Gorlick, Maris et al. 2011). In T cell acute lymphoblastic leukemia it has 
been demonstrated that MK-2206 results in induction of apoptosis, autophagy and cell cycle 
arrest (de Frias, Iglesias-Serret et al. 2009). The treatment of MK-2206 in various cancer 
conditions as a single agent or in combination with other inhibitors has been effective in 
diminishing the tumor growth and reducing cell survival of cancer cells.  Thus MK-2206 has been 
demonstrated as a promising anti-cancer agent that potentially augments the effectiveness of the 
current front line cancer therapeutic drugs.  
2.6.2 Perifosine 
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Perifosine is an allosteric inhibitor that binds the PH domain of Akt, thus preventing the 
translocation to plasma membrane (Pinton, Manente et al. 2012). It inhibits the activation of Akt 
signaling, thus reducing cell survival in many cancer conditions like multiple myeloma, T-cell 
acute lymphoblastic leukemia, NSCLC, prostate and ovarian carcinoma (Ma, Gibson et al. 2006, 
Yang, Fraser et al. 2006, Floryk and Thompson 2008, Richardson, Wolf et al. 2011) . It has been 
reported that perifosine in combination with curcumin results in increased cell death and cell 
proliferation of CRC cells in vivo and in vitro. It is believed that this combination inhibits Akt and 
NF-kB signalling and increases endoplasmic stress and thus plays an anti-tumorigenic role (Chen, 
Wu et al. 2012). The role of perifosine was studied in hepatocellular carcinoma and it was found 
that this Akt inhibitor results in increased apoptosis by affecting the phosphorylation of ERK and 
JNK (Chiarini, Del Sole et al. 2008). In a study in hepatocellular carcinoma it was observed that 
perifosine in combination with cisplatin increases apoptosis by increasing the expression of BAX 
and by reduction in the expression of Bcl-2 (Chiarini, Del Sole et al. 2008). A recent report by 
Richardson et al. has revealed that periforsine in combination with bortezomib shows promising 
results in patients suffering from multiple myeloma with a response rate of 40% (Richardson, 
Wolf et al. 2011). 
2.6.3 Deguelin 
Deguelin is a plant product derived from rotenone, which is used as an important 
chemotherapeutic agent. It plays anti-tumorigenic role by affecting multiple pathways, such as the 
inhibition of PI3K/Akt pathway, suppressing the expression of cyclooxygenase 2 (COX2) and 
cyclin D1 expression (Nair, Shishodia et al. 2006) . Deguelin causes an increase in apoptosis both 
in vivo and in vitro in a dose and time-dependent manner by inhibiting phosphorylation of Akt in 
lung cancer. It is a heat shock protein 90 (Hsp90) inhibitor with potent anti-angiogenic activity 
(Kim, Chang et al. 2008). This drug inhibits Akt activity both via PI3K dependent and PI3K 
independent pathways (Chun, Kosmeder et al. 2003). Deguelin suppresses the growth of colon 
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cancer cells in mice by modulating the NF-kB and Wnt signalling pathway. However, it is a 
potent inhibitor of complex-1 of electron transport chain and its long-term use can result in 
Parkinson’s disease thus making it incompetent for clinical trials (Kim, Chang et al. 2008). Li et 
al. studied the role of deguelin in murine myeloma cell proliferation and observed that it plays a 
pro-apoptotic role by upregulation of BAX, down-regulation of Bcl-2 and activation of caspase3 
(Li, Wu et al. 2012).  
2.6.4 A443654 and Akti1/2 
A443654 is a potent ATP competitive inhibitor of Akt activity. It inhibits all isoforms of Akt with 
equal potency. Another Akt inhibitor Akti1/2, which is an ATP non-competitive inhibitor, 
inhibits Akt1 and 2 but not Akt3 (Gilot, Giudicelli et al. 2010). Both these inhibitors are being 
studied in chronic lymphocytic leukemia (CLL). Treatment of CLL cells with these inhibitors 
results in reduced expression of MCL-1, which is a critical survival protein in CLL cells (de 
Frias, Iglesias-Serret et al. 2009). It has also been shown that A443654 increases phosphorylation 
of Akt at Ser473 thus resulting in increase in Akt activity. This increase in Akt activity is 
considered as a feedback response of the cell to maintain activation of Akt (Han, Leverson et al. 
2007). 
2.6.5 GSK690693 
GSK690693 is a potent ATP competitive Akt inhibitor that inhibits phosphorylation of 
downstream targets. It is given intravenously to patients with hematological malignancy (Levy, 
Kahana et al. 2009). Altmore et al. has studied the effect of this inhibitor on mouse model that 
develop spontaneous athymic lymphoma, endometrial carcinoma or ovarian cancer. Since all 
these mouse models had activated Akt, treatment with GSK690693 results in reduction in tumor 
progression, phosphorylation of Akt substrates, cell proliferation and increased apoptosis 
(Altomare, Zhang et al.). This Akt kinase inhibitor has been shown to reduce tumor growth in 
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xenograft models for ovarian, prostate and breast tumors (Rhodes, Heerding et al. 2008). It has 
been reported that long-term use of this GSK690693 inhibits glycogen synthesis and activates 
glycogenolysis thus resulting in hyperglycemia as one of the major side effects and making this 
drug unfit for further clinical trials (Crouthamel, Kahana et al. 2009). It is being used in 
combination with other inhibitors, such as mTOR inhibitor and have shown to induce cell death 
in non-small lung cancer cells (Jeong, Choi et al. 2012).  
2.6.6 HSP90 inhibitors 
HSP90 is a molecular chaperone which plays an important role in the stability and post-
translational maturation and activation of some of the proteins which are implicated in 
oncogenesis (Mahalingam, Swords et al. 2009). HSP90 is responsible for maturation of certain 
cell signalling proteins such as Raf Serine kinases, CDK4 and receptor tyrosine kinases (Xu, 
Marcu et al. 2002). It has been reported that HSP90 is overexpressed in number of cancers and in 
virally-transformed cells (Flandrin, Guyotat et al. 2008). HSP90 is a dimer and contains an ATP 
binding pocket, which is required for its optimal activity. It was reported that amino acid residues 
(229-309) of Akt are responsible for binding to HSP90. The formation of Akt –HSP90 complex 
stabilizes Akt activity by preventing its dephosphorylation from PP2A. Stabilization of Akt in 
phosphorylated state prevents apoptosis in the normal cells making them tumorigenic (Sato, 
Fujita et al. 2000). Thus, HSP90 has now become an attractive target in anti-cancer therapy. 
Multiple small molecule inhibitors are being used to inhibit HSP90-client protein interaction that 
leads to client protein degradation (Neckers 2002). Whitesell et al. reported that benaoquinone 
anamycins like geldanamycin inhibit HSP90 by binding at the ATP binding pocket and thus 
release the client protein (such as Akt) and directs it to proteasome for degradation, thus resulting 
in shortening of half-life of Akt from 36 h to 12 h (Whitesell, Mimnaugh et al. 1994). 
Geldanamycin is a naturally occurring drug, which is produced by microorganisms and is an 
HSP90 inhibitor, that is being used in combination with chemotherapy and radiotherapy for tumor 
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suppression in preclinical models. In human neuroblastoma and multiple myeloma studies, 
HSP90 inhibitor was combined with Akt inhibitor perifosine demonstrating increased anti-tumor 
activity (Kim, Kang et al. 2003, Mitsiades, Mitsiades et al. 2006). It is presently in phase II 
clinical trial for Her2-positive breast cancer in combination with Herceptin (Modi, Stopeck et al. 
2007). 
2.7 Conclusions 
As discussed in this chapter, Akt acts a nodal onco-protein critical for regulating cell survival and 
metastasis of cancer cells. Thus, targeting Akt as a potential anti-metastatic therapeutic strategy 
either as a single agent or in combination holds significant promise.  
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Figure 2.1: PI3K/Akt signalling in cancer 
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Figure 2.2: Akt isoform functions in cancer 
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Figure 2.2: 
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Figure 2.3: Molecular interactions of Akt2 in colorectal cancer metastasis signalling  
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Figure 2.3: 
 
 
 
 
 
 
 
 
76 
 
Figure 2.4: Loss of autocrine TGFβ leads to complex formation between Akt & Smad3 
during stress  
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Figure 2.4: 
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Figure 2.5: TGFβ/PKA mediated Akt regulation leading to cell death in CRC 
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Figure 2.5: 
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3. Materials and Methods 
3.1 Cell lines and reagents 
GEO (Wang, Han et al. 1996) and CBS (Ye, Foster et al. 1999) colon carcinoma cells were 
cultured in serum-free (SF) medium (McCoy’s 5A with pyruvate, vitamins, amino acids and 
antibiotics) supplemented with 10 ng/ml epidermal growth factor, 20 g/ml insulin and 4 g/ml 
transferrin at 37C in a humidified atmosphere of 5% CO2 (Chowdhury, Howell et al. 2011, 
Chowdhury, Howell et al. 2011). When the cells were under GFDS (growth factor deprivation 
stress) (Wang, Yang et al. 2008), they were cultured in Supplemental McCoy’s (SM) medium in 
the absence of growth factor or serum supplements for the indicated times as described previously 
(Wang, Yang et al. 2008). HCT 116 (IGF1R- independent colon cancer cell lines) and MiaPaCa 
(pancreatic cancer cells with constitutive activation of IGF-1R) cells were used as control to 
demonstrate the specificity of the dose of the kinase inhibitor. The in vivo experiments were 
carried out with GEO cells stably transfected with a GFP vector to visualize the tumor size. MK-
2206 was provided by Merck and Co., Inc. MK-2206 was dissolved in DMSO for in vitro 
experiments. However, for in vivo experiments 30% Captisol (Cydex Pharmaceuticals) was used 
as a vehicle for the drug. In in vitro experiments the control cells were treated with DMSO. The 
control animals also received 30% Captisol. AIF inhibitor, N- Phenylmaleimide was purchased 
from Sigma.  
3.2 Inducible knockdown of Akt isoforms 
Three different shRNA in pTripZ Doxycycline (Dox) inducible vector for each Akt isoform were 
purchased from Thermoscientific Open Biosystems (Clone ID for Akt1: 
V2THS_192049:V3THS_358718:V3THS_358720) (Clone ID for Akt2: V2THS_237948: 
V3THS_325553: V3THS_325558) (Clone ID for Akt3: V2THS_68871: V2THS_68872: 
V2THS_68874) (Clone ID for Non-targeting: RHS4743). The pTripZ vector has Red Florescent 
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Protein (RFP), which is induced on addition of Dox, thus the cells infected with this vector show 
red florescence under immunofluorescence microscope on treatment with Dox. HEK293T cells 
were transfected with the vector. The lentivirus formed was infected in GEO and CBS GFP- 
tagged cells. The cells were selected and maintained in puromycin (4ug/ml) (Geng, Chaudhuri et 
al. 2013). The shRNA was induced by adding Dox (1ug/ml) for five-days. 
3.3 shRNA mediated knockdown of MTSS1 
MTSS1 shRNA and Non Silencing shRNA in GIBz vector was purchased from Open Biosystems 
(Clone ID for MTSS1: V2THS_229344 Clone ID for Non-targeting: RHS4346). Transfections 
were done in HEK293T cells followed by infection in GEO GFP Akt2 knockdown cells using 
manufacturer’s instructions.  
3.4 Retroviral knockdown of Akt1 and Akt2 
Small hairpin RNA sequence for Akt1si, Akt2si, Akt3si and scramble si were cloned and 
expressed in a retroviral expression vector pSUPER.Retro.Puro (Oligoengine). 293T derived Phi-
NX cells were used for transfection. A 19-nucleotide sequence for Akt1,   Akt2 and Akt3 were 
designed from Dharmacon si design center. The target sequence for Akt1 
5’GAGACTGACACCAGGTATT 3’ was 1634 bases while that for Akt2 
5’TGAATGAGGTGTCTGTCAT 3’ selected was 301 bases downstream of 5’UTR. Akt3 target 
sequences selected were 5’GCAAAATGCCAGTTAATGA 3’. Another non-targeting small 
hairpin siRNA was used as an experimental control. The GEO cells were stably transfected with 
siRNA to reduce the expression of Akt1, Akt2 and Akt3. The cells were selected with Puromycin 
(4 g/ml) and the resistant cells were pooled. Stable cell lines with Akt1, Akt2 and Akt3 
knockdown were maintained in serum free medium with puromycin (4 g/ml).  
3.5 RNA interference studies 
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XIAP siRNA (ON-TARGET plus Human XIAP (331) siRNA smart pool) , AIF si RNA (ON-
TARGET plus Human AIF siRNA smart pool)  were purchased from Thermo scientific and 
transient transfections were done as per manufacturer’s protocol. 
3.6 Proliferation Assay 
GEO and CBS cells were plated at a density of 8X10
3
 cells per well in a 96 well plate. After 72 h 
the cells were treated with increasing concentrations of MK-2206. Cell proliferation was 
measured after 48 h by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) 
assay as described previously (Hu, Patil et al. 2008). 
3.7 DNA Fragmentation Assay 
Cells were seeded in 96 well plates at the same density as for proliferation assays. MK-2206 was 
treated 72 h after plating the CRC cells. DNA fragmentation assays were performed after 48 h of 
treatment using a Cell Death Detection ELISA plus kit (Roche) according to the manufacturer’s 
protocol as described previously (Wang, Yang et al. 2008). To confirm AIF mediated cell death, 
DNA fragmentation was performed by pretreating the cells with AIF inhibitor (50M/L) for 1 h 
prior to treatment with MK-2206 for 48 h. Additionally a DNA fragmentation assay was 
performed after siRNA-mediated knockdown of AIF followed by treatment with MK-2206 for 48 
h.  GEO cells were treated with XIAP siRNA for 48 h and then DNA fragmentation was 
performed to confirm the effect of XIAP on cell death.  
3.8 Transwell Migration Assay  
 Transwell migration inserts with 1.2u pores were purchased from BD Biosciences 
(Cat#P1XP01250). 80,000 cells were plated in SM media in the transwell.  0.7 ul of serum-rich 
media was kept in the bottom chamber. The transwell inserts with the cell suspension was 
carefully placed into the chamber with serum-rich media. The plate was incubated for 32 hrs. The 
cells were fixed using 4% paraformaldehyde followed by staining with crystal violet. 
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3.9 RNA Isolation and Quantitative Real Time PCR 
 RNA were collected using the High Pure RNA Isolation kit (Roche Applied Science)(Wang, 
Yang et al. 2008). The two-step quantitative PCR using TaqMan reagents were performed 
according to the manufacturer's instructions (Applied Biosystems). The mRNA expression was 
normalized to GAPDH. 
3.10 RT
2 
Profiler PCR Array Analysis  
Real-time PCR was performed on cDNA samples from Non-targeting shRNA and Akt isoform 
knockdowns using the Human Tumor Metastasis RT
2
 Profiler PCR array (Super Array 
Bioscience, Frederick, MD, USA) in a C1000 Thermal Cycler from BioRad according to 
manufacturer’s instructions. Data were normalized for GAPDH levels by the ΔΔCt method. 
3.11 Subcellular fractionation 
Cells were washed with ice-cold phosphate buffer saline (PBS) twice. The cells were suspended 
in 1ml of PBS and centrifuged for 1 min at 4C.  The supernatant was removed, the pellet was 
dissolved in 1ml of CE buffer, and samples were vortexed for about 15 sec. The samples were 
kept on ice for an hour, passed through a syringe every 20 minutes and centrifuged for 1 min. The 
supernatant was collected and the pellet was left out to isolate nuclear extract. The supernatant 
was centrifuged again for 1 min to get rid of any debris. The supernatant isolated now was 
designated as the cytoplasmic extract and was stored at -80C. Nuclear extract buffer was added 
to the pellet and the sample was vortexed for 20 seconds. The samples were kept on ice for an 
hour and sonicated twice for 10 seconds at 60% amplitude. The samples were centrifuged for 20 
min at 4C and supernatant collected was stored at -80C. 
3.12 Western Blot Analysis and Immunoprecipitation 
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Cells were lysed in a buffer consisting of 50 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 0.5% 
NP40, 50 mmol/L NaF, 1 mmol/L NaVO3, 1 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L 
DTT, 25 g/mL aprotinin, 25 g/mL trypsin inhibitor, and 25 g/mL leupeptin. The supernatants 
were cleared by centrifugation at 4C. Protein concentration was measured by bicinchoninic acid 
assay (Pierce) using a Biotek 96 well plate reader. Protein (30–100 g) was fractionated by 
electrophoresis on a 10% acrylamide denaturing gel and transferred onto a nitrocellulose 
membrane (Life Science, Amersham) by electroblotting. The transfer on the nitrocellulose 
membrane was routinely confirmed by Ponceau S staining. The membrane was blocked with 5% 
nonfat dry milk in TBST [50 mmol/L Tris (pH 7.5), 150 mmol/L NaCl, 0.05% Tween 20] for 1h 
at room temperature or overnight at 4C and washed in TBST. The membrane was then incubated 
with primary antibodies at 1:200-1:1000 in TBST overnight at 4C. After washing with TBST for 
15 min, the membrane was incubated with horseradish peroxidase–conjugated secondary 
antibody (Life Science, Amersham) at 1:1000 dilutions for 1h at room temperature. The proteins 
were detected by the enhanced chemiluminescence system (Amersham). Immunoprecipitation 
was performed with 500 g of protein samples using magnetic beads (Millipore) according to 
manufacturer’s protocol. Antibodies were purchased from Cell Signaling for tAkt, pAkt (S473), 
pAkt(T308), AIF (Apoptosis Inducing Factor), pEzrin (Thr567), Akt1, Akt2, Akt3 survivin, Bad 
and pBad (S136). Ezrin antibody was purchased from Santa Cruz. XIAP antibody was purchased 
from Abcam. 
3.13 Immunofluorescence 
The translocation of AIF from mitochondria to nucleus was determined by an 
immunofluorescence assay. GEO cells were plated on a cover slip in a six well plate. When the 
cells were 60-70% confluent, culture medium with 400nm of Mitotracker (CMX Ros, Invitrogen) 
was added to the cells. The cells were checked for red fluorescence under the microscope after 
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one hour.  The cells were stained, washed with growth medium and fixed by placing in ice-cold 
methanol for 5 minutes. The cells were washed with PBS, permeabilized by incubating with PBS 
containing 0.1% Triton X-100 for 15 minutes and subsequently blocked with 10% normal goat 
serum. After one hour of blocking, the cells were incubated with primary antibody for AIF 
(1:100) for 2h. Fluorescein isothiocyanate- conjugated anti rabbit antibody (FITC) was used as 
the secondary antibody. Nuclei were counter stained with 4’-6 diamino-2- phenylindole and 
mounted on glass slide in anti fade vecta shield mounting medium (vector labs). An LSM 510 
microscope (Carl Ziess GmbH, Oberkochen, Germany) was used to perform laser confocal 
microscopy.  
3.14 Xenograft Studies 
All the experiments involving animals were approved by the University of Nebraska Medical 
Center Institutional Animal Care and Use Committee. 3-5 week old athymic nude mice (N=16) 
were purchased from NCI. 7X10
6 
GEO GFP-labeled cells were subcutaneously injected on one 
side in the right flank pad of mice and allowed to form xenografts. When the tumor size was 
approximately 100 mm
3
, 120 mg/kg body weight of MK-2206 was administered orally. Captisol 
was used as a vehicle for the drug and the control animals were treated with vehicle only. MK-
2206 was given orally for 3 weeks on alternate days. The dose and the duration mentioned in the 
study have been provided by Merck and Co. Tumor growth and body weight were measured 
every other day. The tumor size was measured manually with calipers, and the tumor volume was 
calculated using the formula (l
2
 x h x /6). We used Near-IR enhanced Macro Imaging System 
Plus Cooled with the LT-99D2 with the Dual Tool dual excitation upgrade for viewing the 2D 
image of the tumor as well as to image the mice. All in vivo characterizations were confirmed in 
at least 3 independent control and MK-2206 treated animals.  
3.15 Orthotopic Implantation Studies 
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All the experiments involving animals were approved by the University of Nebraska Medical 
Center Institutional Animal Care and Use Committee. 3-5 week old athymic nude mice (N=75, 
25 animals in each group) were purchased from NCI. Orthotopic implantation was performed as 
previously described (Wang, Yang et al. 2008, Geng, Chaudhuri et al. 2013). Briefly, green 
fluorescent protein (GFP)-labeled GEO Non-targeting sh, Akt1 sh and Akt2 shcells (7 X 10
6 
) 
were subcutaneously injected onto the dorsal surfaces of separate athymic nude male mice and 
allowed to grow to 500 mm
3
. Once xenografts were established, they were excised and minced 
into 1-mm3 pieces. Two of these pieces were then orthotopically implanted into the colon of 
other athymic nude mice. For operative procedures, animals were anesthetized with isoflurane 
inhalation. A 1-cm laparotomy was performed and the cecum and ascending colon were 
exteriorized. Using 7X magnification and microsurgical techniques, the serosa was disrupted in 
two locations. Pieces of xenograft (1 mm
3
) were subserosally implanted using an 8–0 nylon 
suture at the disrupted serosal locations. The bowel was then returned to the peritoneal cavity and 
the abdomen was closed with 5–0 vicryl suture. Fluorescence imaging was performed weekly on 
the animals to follow tumor growth (LightTools). After six weeks of orthotopic implantation, 
Dox (2mg/ml) was introduced in the drinking water of the animals for 3 weeks.  Animals were 
euthanized at 9 weeks after implantation. Organs were explanted, imaged, and immediately 
placed in buffered 10% formalin. Tissues were then processed and embedded in paraffin. 
Histological slides were cut for H&E staining. Metastases were determined by histological 
evaluation of each liver lobe and both lungs as described in detail  (Guo, Rajput et al. 2007, 
Wang, Yang et al. 2008).  
3.16 Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) 
assay 
Sections (4 M) from paraffin-embedded blocks were stained according to the Apotag terminal 
nucleotidyl transferase mediated nick end labeling (TUNEL) assay kit. The apoptotic rates were 
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determined by counting the number of positively stained apoptotic bodies at 40X magnification. 
Ten different fields were randomly selected per slide for analysis. The ratio of the average 
number of apoptotic cells to the total number of cells counted was used to determine apoptotic 
rates (Wang, Yang et al. 2008, Geng, Chaudhuri et al. 2013).  
3.17 Hematoxylin and Eosin staining and Ki67 staining  
Sections (4 M) from paraffin-embedded blocks were used for H and E staining and for Ki67 
IHC using antibody for Ki67 from BD biosciences. Ki67 is a non-histone nuclear antigen present 
in late G1, G2 and S phase of cell cycle but absent in G0. The dilution of Ki67 antibody used was 
1:100. The proliferation rate was determined quantitatively by utilizing Definience software 
(public domain software). Ten different, but histologically similar fields per sample were selected 
for analysis (Wang, Yang et al. 2008, Geng, Chaudhuri et al. 2013). 
3.18 Immunohistochemistry  
The slides were deparafinized by keeping them at 60C for 1 h and then rehydrated using graded 
alcohol for 5 min each. Subsequently the slides were treated with 0.3% H2O2/methanol for 10 min 
and then submerged in 95C citrate buffer (pH=7.8) for 15 min. Blocking was performed in 5% 
normal goat serum for 1h at room temperature and then the slides were incubated with primary 
antibody for Akt1, Akt2, MTSS1 and XIAP at 4C overnight.  The slides were treated with 
biotinylated secondary antibody for 30 min at RT, followed by incubation with streptavidin 
peroxidase complex (Invitrogen). Reaction products were developed using diaminobenzidine 
containing 0.3% H2O2 as a substrate for peroxidase (Dako). Nuclei were counterstained with 
hematoxylin (Protocol)(Wang, Yang et al. 2008, Geng, Chaudhuri et al. 2013). To determine the 
difference in staining intensity of Akt1, Akt2, MTSS1 and XIAP, 10 different but histologically 
similar fields were selected per sample and the slides were analyzed Definience Tissue Studies 64 
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(Dual 4.1) software. The staining intensity measured by the software was plotted using Graph pad 
5.0. 
3.19 Statistical analysis  
 Statistical analysis was performed using Graph pad 5.0 software for student’s t test. A p 
 value of less than 0.05 was considered significant. 
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4. Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF 
and Ezrin in colorectal cancer. 
4.1 Abstract 
There is extensive evidence for the role of aberrant cell survival signaling mechanisms in cancer 
progression and metastasis. Akt is a major component of cell survival-signaling mechanisms in 
several types of cancer. It has been shown that activated Akt stabilizes XIAP by S87 
phosphorylation leading to survivin/XIAP complex formation, caspase inhibition and 
cytoprotection of cancer cells. We have reported that TGFβ/PKA/PP2A-mediated tumor 
suppressor signaling regulates Akt phosphorylation in association with the dissociation of 
survivin/XIAP complexes leading to inhibition of stress-dependent induction of cell survival. 
IGF1R-dependent colon cancer cells (GEO and CBS) were used for the study. Effects on cell 
proliferation and cell death were determined in the presence of MK-2206. Xenograft studies were 
performed to determine the effect of MK-2206 on tumor volume.  The effect on various cell death 
markers such as XIAP, survivin, AIF, Ezrin, pEzrin was determined by western blot analysis. We 
characterized the mechanisms by which a novel Akt kinase inhibitor MK-2206 induced cell death 
in IGF1R-dependent colorectal cancer (CRC) cells with upregulated PI3K/Akt signaling in 
response to IGF1R activation. MK-2206 treatment generated a significant reduction in tumor 
growth in vivo and promoted cell death through two mechanisms. This is the first report 
demonstrating that Akt inactivation by MK-2206 leads to induction of and mitochondria-to-
nuclear localization of the Apoptosis Inducing Factor (AIF), which is involved in caspase-
independent cell death. We also observed that exposure to MK-2206 dephosphorylated Ezrin at 
the T567 site leading to the disruption of Akt-pEzrin-XIAP cell survival signaling. Ezrin 
phosphorylation at this site has been associated with malignant progression in solid tumors. The 
identification of these two novel mechanisms leading to induction of cell death indicates MK-
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2206 might be a potential clinical candidate for therapeutic targeting of the subset of IGF1R-
dependent cancers in CRC. 
4.2 Introduction 
The interplay between oncogenic signal transduction pathways and their downstream mediators 
has been extensively characterized over the past two decades. These signaling events are 
transmitted by protein-protein interactions that are frequently regulated by phosphorylation events 
(Shtilbans, Wu et al. 2008). PI3K/Akt signaling is a major signal transduction cascade involved in 
the regulation of a number of cellular processes including cellular proliferation, survival, and 
metabolism. PI3K/Akt signaling has been implicated in the progression and metastasis of a wide 
range of cancers (Grabinski, Bartkowiak et al. 2011). The Akt protein kinase, comprised of 3 
isoforms (Akt1, 2 and 3), is a direct downstream effector of PI3K, which becomes fully activated 
by phosphorylation at the T308 and S473 sites (Fayard, Xue et al. 2011, Grabinski, Bartkowiak et 
al. 2011). Activated Akt is frequently observed in poorly differentiated tumors where it bridges 
the link between various oncogenic receptors and pro-survival cellular functions making the 
tumor cells highly invasive and less responsive to chemotherapeutic drugs (Agarwal, Brattain et 
al. , Grabinski, Bartkowiak et al. 2011).  
The Akt effects on aberrant cell survival are mediated by the regulation of a number of 
critical downstream proteins that have been implicated in apoptosis and anoikis including Bad, 
Caspase9, IKK, Mdm2 and FHKR (Janes and Watt 2004, Zhan, Zhao et al. 2004, Shtilbans, Wu 
et al. 2008). Akt is also involved in cell cycle regulation by phosphorylation and inactivation of 
the cyclin dependent kinase inhibitors p21 and p27/kip1 (Nicholson and Anderson 2002, 
Shtilbans, Wu et al. 2008). Constitutively activated Akt has been linked to epithelial-to-
mesenchymal transition (EMT) by regulating MMPs resulting in reduced cell-to-cell adhesion, 
increased motility and invasion. It has also been reported that Akt–driven EMT may confer the 
motility required for malignant progression and dissemination of cancer cells to distant organs 
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(Grille, Bellacosa et al. 2003, Larue and Bellacosa 2005). Recently, we identified a new pathway 
by which TGF/PKA/PP2A signaling deactivates Akt phosphorylation leading to downregulation 
of IAPs, XIAP and survivin in colorectal cancer (CRC) cells (Chowdhury, Howell et al. 2011, 
Chowdhury, Howell et al. 2011). 
The broad roles of this enzyme in cancer have established Akt as an attractive therapeutic 
candidate in cancer. Small molecule inhibitors of the PI3K/Akt pathway are being developed for 
clinical use. Several Akt inhibitors have been synthesized, including MK-2206, a novel allosteric 
kinase inhibitor of Akt (Cheng, Zhang et al. 2012, Lai, Liu et al. 2012, Liu, Liu et al. 2012). MK-
2206 binds to the pleckstrin-homology (PH) domain of Akt and thereby inhibits PDK1 binding 
and activation of Akt. This results in change in confirmation of Akt and its inability to localize to 
the plasma membrane (Cheng, Zhang et al. 2012, Lai, Liu et al. 2012, Liu, Liu et al. 2012). MK-
2206 has shown promising preclinical activity and is currently undergoing phase II clinical 
evaluation. Although the specific mechanisms underlying the anti-cancer activity of MK-2206 
remain to be fully elucidated, MK-2206 has been shown to induce cell cycle arrest and apoptosis 
(Cheng, Zhang et al. 2012, Lai, Liu et al. 2012, Liu, Liu et al. 2012).  
We now report that MK-2206 induces anti-tumor activity in a subset of human CRC cell 
lines characterized by their dependence on IGF1R signaling which leads to PI3K/Akt 
upregulation for cell survival (Hu, Patil et al. 2008). Strikingly, exposure to MK-2206 resulted in 
the generation of 2 mechanisms of cell death, which have not previously been documented for 
this drug. The MK-2206-dependent death of IGF1R-dependent CRC cells in vitro and in vivo was 
characterized by Apoptosis Inducing Factor (AIF) induction and its mitochondria-to-nuclear 
translocation, which is known to induce caspase-independent cell death (Daugas, Nochy et al. 
2000, Wang, Zhang et al. 2007). Additionally, MK-2206-dependent cell death was also 
characterized by the inactivation of the cytoskeletal organizing protein Ezrin at T567 leading to 
the loss of Inhibitor of Apoptosis (IAP) family protein XIAP. It has been reported that aberrant 
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increase of Ezrin phosphorylation at the T567 site generates increased cell survival and metastatic 
capabilities of cancer cells (Wu, Khan et al. 2004, Li, Wu et al. 2008, Chen, Wang et al. 2011, 
Nakabayashi and Shimizu 2011). In summary, our results indicate that MK-2206 is a promising 
therapeutic candidate for treatment of IGF1R-dependent CRC characterized by PI3K/Akt 
signaling upregulation.  
4.3 Results  
4.3.1 Effect of MK-2206 on apoptosis of CRC cells -MK-2206 inhibits the phosphorylation of 
Akt at both Ser473 and Thr308 in two IGF1R-dependent GEO and CBS colon cancer cell lines. 
However the total Akt protein levels remain unchanged (Figure 4.1A, 4.1B). HCT116 showed a 
marginal loss of pAkt (S473) however MiaPaCa cells showed a robust loss of pAkt with MK-
2206 treatment (Figure S1). We performed MTT assays to study the effect of MK-2206 on 
proliferation of IGF1R-dependent colon cancer cells. MK-2206 treatment for 48h showed a 
concentration-dependent reduction in cell proliferation (Figure 4.2A). The IC50 value of MK-2206 
for GEO cells was observed to be 350 nM. Treatment with 500 nM of MK-2206 reduced cell 
proliferation by approximately 75%. DNA fragmentation assays were performed to determine the 
effect of MK-2206 treatment on cell death. It was observed that cell death increased in a 
concentration dependent manner on treatment with MK-2206 as shown in Figure 4.2B. Treatment 
with 500nM of MK-2206 increased cell death by approximately 85% as compared to control.  
Western blot analysis of various apoptotic markers revealed a decrease in Bad phosphorylation at 
Ser136 following treatment with MK-2206. (Figure 4.2C). Bad can undergo phosphorylation at 
two sites (Ser112 and Ser136). Akt preferentially phosphorylates Bad at Ser136 (Datta, Dudek et 
al. 1997). Phosphorylated Bad at Ser136 associates with cytoplasmic14-3-3 proteins. Treatment 
with MK-2206 results in reduced interaction of pBad with 14-3-3 due to increased cell death 
(Figure 4.2D). On the other hand dephosphorylated Bad interacts with Bcl-xL a pro-survival 
molecule, and inactivates it to generate cell death (Datta, Dudek et al. 1997). We observed that 
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there was an increase in the interaction of Bcl-xL with total Bad on treatment with MK-2206 
which results in more inactivation of Bcl-xL thus leading to increased cell death (Figure 4.2E). 
Furthermore, we observed a reduction in the interaction of Bad with 14-3-3 on treatment of MK-
2206 (Figure 4.2D). It has been determined previously that there is an increase in the expression 
of IAPs (Survivin and XIAP) in colon, lung and breast cancer. There was an increase in cell death 
on transient knockdown of XIAP as determined by DNA fragmentation, which confirms that 
XIAP is responsible for increased survival of cells by inhibiting caspase mediated cell death 
(Figure S2). We observed a reduction in the expression of survivin and XIAP on treatment with 
MK-2206 in vitro and in vivo (Figure 4.2C, S3). Therefore, MK-2206 regulates aberrant cell 
survival of CRC cells by down regulating IAPs in CRC cells.  
4.3.2 MK-2206 inhibits colon tumor xenograft growth - The antitumor activity of MK-2206 on 
GEO colon cancer xenografts was determined by injection of GEO-GFP cells subcutaneously into 
the flank of athymic nude mice. One week after implanting the cells, MK-2206 was administered 
at 120 mg/kg body weight by oral gavage for three weeks on alternate days. As shown in Figure 
4.3A, MK-2206 significantly inhibits tumor growth. The tumor volume was found to be 
significantly reduced in MK-2206 treated animals (P<0.01) as compared to control animals 
(Figure 4.3B, 3C).  The excised tumors from control animals showed an average weight of 2.5g 
compared to treated animal tumors weighing approximately 0.8g. (Figure 4.3D). Importantly, 
there was no significant decrease in the body weight in treated animals compared to control 
(Figure S4). 
The expression of pAkt S473 was found to be reduced by treatment with MK-2206 in 
vivo by IHC(Figure 4.4A). Densitometry of the IHC images showed a significant reduction in the 
expression of pAkt S473 in treated animals as compared to control animals (p<0.02) as shown in 
Figure 4.4B. The loss of phosphorylation of Akt was further confirmed by western blot analysis 
of MK-2206-treated tumor tissue lysates showing a reduction in pAkt at both S473 and T308 
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sites, in comparison to the control xenograft tumors (Figure 4.4C). However the change in total 
Akt (termed here as tAkt) was not statistically significant (Figure S5, S6).   
4.3.3 MK-2206 inhibits cell proliferation and cell death in vivo - H&E staining indicated that 
MK-2206 treatment induced an increase in necrosis that was observed by scanning the entire 
tissue section using an image scanner and visually inspecting the necrotic areas (Figure S7). Cell 
death (quantified by TUNEL assay) was also observed to be significantly increased following 
MK-2206 treatment (Figure 4.5A, 4.5B). MK-2206 treatment also resulted in reduced cell 
proliferation as measured by Ki67 staining (Figure 4.5C, 4.5D). Figure S8 shows the images of 
control and treated mice just before euthanizing. 
4.3.4 Mechanisms of cell death by MK-2206 - MK-2206 treatment promotes cell death both in 
vitro and in vivo. We characterized the molecular effects underlying MK-2206 mediated cell 
death in colon cancer cells. Western blot analysis showed that there was an increase in the 
expression of AIF protein after treatment with MK-2206 (Figure 4.6A). The mechanism by which 
the loss of pAkt might be related to this induction is not known. Cregan et al. (2002) previously 
reported that AIF is responsible for caspase-independent apoptosis (Cregan, Fortin et al. 2002) by 
undergoing translocation from the mitochondria to nucleus. To determine the migration of AIF, 
we prepared nuclear and cytoplasmic extracts of untreated cells and cells treated with MK-2206 
at 500nM (since there was a higher increase in expression of AIF at 500nM). Immunoblot 
analysis indicated higher AIF expression in nuclear extracts of cells treated with MK-2206 as 
compared to nuclear extracts of untreated cells (Figure 4.6C), thus confirming that treatment by 
MK-2206 stimulates translocation of AIF to the nucleus. Translocation of AIF was further 
confirmed by immunofluorescence using confocal microscopy (Figure 4.6B). AIF mediated cell 
death was further confirmed by AIF inhibitor N-Phenylmaleimide (Daugas, Nochy et al. 2000, 
Wang, Zhang et al. 2007). Treatment with the AIF inhibitor at a concentration of 50 M/L for 1 h 
prior to treatment with MK-2206 for 48 h shows a reduction in cell death thus confirming MK-
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2206 mediated cell death is through stimulation of AIF (Figure 4.6D). Additionally loss of AIF 
by siRNA-mediated knock down results in reduction in cell death in presence of MK-2206 as 
determined by DNA fragmentation assay (Figure S9) 
In addition to caspase-independent cell death, we also observed caspase-dependent cell 
death through XIAP downregulation following treatment with MK-2206 (Figure 4.2D). It has 
been shown that Akt2 regulates phosphorylation of Ezrin at T567 leading to the translocation and 
activation of the Na
+
-H
+
 exchanger (NHE3) (Shiue, Musch et al. 2005) and NHE regulatory 
factor 1 (NHERF1) supports Akt-dependent cell survival (Wu, Khan et al. 2004). We observed 
that MK-2206 might inactivate Ezrin by affecting its phosphorylation at the T567 site ( Figure 
4.7A, 4.7B) in vitro as well as in vivo. The loss of Ezrin phosphorylation is known to affect 
cellular survival and proliferation (Wu, Khan et al. 2004). Stable retroviral knockdown of Akt2 
also results in reduction in Ezrin phosphorylation at T567. However there was no change in 
expression of total Ezrin on knockdown of Akt2 as shown in (Figure 4.7C). Interestingly no such 
loss of phospho Ezrin T567 was observed with Akt1 and Akt3 knockdown (Figure 4.7D, S10). 
Furthermore, Ezrin knock down resulted in complete loss of XIAP and survivin (Figure S11). 
Therefore, it appears that Akt2 plays an important role in regulating cell survival mediated by the 
Akt2-pEzrinT567-XIAP axis. MK-2206 treatment caused AIF activation and Ezrin 
dephosphorylation at the T567 site and, ultimately, this leads to loss of survivin/XIAP-mediated 
aberrant cell survival and increased cell death.  
4.4 Discussion 
Extensive drug development efforts and clinical evaluations are underway targeting the aberrant 
cell survival properties associated with PI3K/Akt signaling in regulating cancer progression and 
metastasis (Shtilbans, Wu et al. 2008). Inhibition of Akt activation by small molecule kinase 
inhibitors is an attractive candidate for targeting aberrant cell survival associated with malignant 
progression and metastasis and could be effective in the treatment of CRC. MK-2206 is a novel 
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Akt allosteric kinase inhibitor, which is currently in clinical evaluation (Cheng, Zhang et al. 2012, 
Lai, Liu et al. 2012, Liu, Liu et al. 2012).  
Several studies have described MK-2206 effects as a single agent or in combination with 
other inhibitors (e.g. PI3K or mTOR inhibitors) on cell proliferation and/or cell death. Gorlick 
et.al. (2011) demonstrated a significant reduction in tumor volume in vivo and decreased cell 
survival in vitro in pediatric cancer cell lines following MK-2206 treatment (Gorlick, Maris et al. 
2011). Simoni et.al. (2012) studied the effect of MK-2206 in T cell acute lymphoblastic leukemia, 
demonstrating cell cycle arrest in G0/G1 phase, apoptosis and autophagy (Simioni, Neri et al.). 
Ma et.al. (2012) showed that MK-2206 treatment in nasopharyngeal carcinoma cells (NPC) 
induced cell cycle arrest and apoptosis (Ma, Lui et al.). Similarly, we observed that MK-2206 
treatment in the IGF1R-dependent GEO cells reduced cell proliferation and increased cell death 
in a concentration-dependent manner (Figure 4.5.2A, 2B), while MK-2206 has been shown to be 
effective in causing cell death in different types of cancer. However, specific mechanisms 
associated with MK-2206-mediated cell death have not been characterized. This study identifies 
molecular mechanisms involved in MK-2206-mediated cell death in IGF1R- dependent CRC 
cells in response to Akt inhibition. Identification of specific mechanisms may generate new 
therapeutic targets that offer potential for enhancing death of CRC cells. The mechanistic novelty 
of this study is our identification of two pathways whereby MK-2206 treatment leads to control 
of aberrant cell survival and induction of cell death in vitro and in vivo.  
We studied the expression of various apoptosis regulators following exposure to MK-
2206. As expected, a reduction in phospho-Bad (pBad) at the Ser 136 site was observed (Figure 
4.2D), which is known to be regulated by Akt signaling (Datta, Dudek et al. 1997). It is known 
that pBad interacts with 14-3-3, a major mediator of cell survival providing an anti-apoptotic 
milieu to the cellular environment (Muslin, Tanner et al. 1996). We observed that treatment with 
MK-2206 results in reduced 14-3-3 interaction with pBad (Ser136) indicating that MK-2206 
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results in reduction in cell survival through this mechanism. The protein expression of Bad 
remained unchanged following MK-2206 treatment; however, there was an increase in the 
interaction of Bad with Bcl-xL. Bad inactivates Bcl-xL thus leading to increases in cell death. 
Additionally we observed a decrease in interaction of Bad with 14-3-3 on treatment with MK-
2206 thus suggesting that Bad remains activated thus leading to apoptosis.  
Strikingly, we made the observation that MK-2206 exposure led to an induction of pro-
apoptotic protein AIF and its translocation from mitochondria to the nucleus of the GEO cells 
(Figure 4.6 A-C). It has been reported that AIF is responsible for caspase-independent death in 
ovarian cancer cells (Yang, Fraser et al. 2008),(Cregan, Fortin et al. 2002, Cheung, Melanson-
Drapeau et al. 2005). AIF is localized in the mitochondria but upon activation it translocates to 
the nucleus and causes DNA fragmentation (Susin, Lorenzo et al. 1999). However, the 
mechanism that regulates AIF induction leading to its caspase-independent apoptotic functions is 
not well understood. Treatment with AIF inhibitor resulted in reduced cell death thus indicating 
that AIF is responsible for cell death mediated by MK-2206. 
MK-2206 treatment of GEO cells reduced survivin and XIAP levels both in vivo and in 
vitro (Figure 4.2D, S3). Survivin and XIAP are key cell survival-associated proteins that have 
been characterized as having an important role in metastasis (Mehrotra, Languino et al. 2010). 
XIAP binds to caspases3, 7 and 9, thereby inhibiting their pro-apoptotic activity (Dohi, Xia et al. 
2007, Mehrotra, Languino et al. 2010). During stress conditions, mitochondrial XIAP and 
survivin migrate to the cytosol forming a survivin/XIAP complex, which inhibits caspases and 
promotes cytoprotection (Dohi, Xia et al. 2007). Dan et.al (2004) made the novel finding that Akt 
phosphorylates XIAP at a stabilizing Ser87 site (Dan, Sun et al. 2004). We demonstrated that 
TGF/PKA signaling regulates aberrant cell survival in IGF1R-dependent CRC cells by 
disengaging survivin/XIAP complex formation thus causing caspase activation and inducing cell 
death. We sought to determine the mechanism by which MK-2206 increased XIAP loss and cell 
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death. It was observed that MK-2206 treatment dephosphorylates Ezrin at the Thr567 site (Figure 
4.7A, 4.7B). However, no change in total Ezrin protein expression was observed. Ezrin is a 
member of Ezrin-radixin-moesin (ERM) protein family that plays a key role in cancer 
progression and metastasis in a wide range of cancers, including CRC (Turunen, Wahlstrom et al. 
1994). Ezrin is found in a closed conformation in the cytosol. Ezrin phosphorylation at Thr567 
leads to its activation and conformational change to an open conformation, resulting in its 
localization to the plasma membrane for its oncogenic-associated functions (Fievet, Gautreau et 
al. 2004). Several kinases are known to phosphorylate Ezrin at T567 including Rho kinase and 
PI3K/Akt (Ng, Parsons et al. 2001). We performed siRNA knockdown of Ezrin and observed a 
complete loss of XIAP and survivin (Figure S11). Thus, we have found that MK-2206 treatment 
inhibits the Akt-pEzrinT567-XIAP cell survival-signaling axis leading to a caspase-dependent 
cell death in the IGF1R-dependent CRC cells, in addition to caspase independent cell death 
accompanying AIF translocation from the mitochondria to the nucleus.  
Stable knockdown of Akt2 in the IGF1R-dependent and highly metastatic colon cancer 
cell line GEO was performed to give a better understanding of the mechanism of cell death 
mediated by loss of pEzrin. Loss of Akt2 resulted in decreased the activation of Ezrin since there 
was a loss of phosphorylation of Ezrin at the T567 site. Besides loss of pEzrin we also observed a 
reduction in the expression of XIAP on knockdown of Akt2. However, there was no such loss of 
pEzrin on knockdown of Akt1 and Akt3 in GEO cells. Thus we can conclude that loss of the 
Akt2 isoform is responsible for Akt-pEzrin-XIAP mediated cell death. 
4.5 Conclusion 
We provided novel mechanistic insights on MK-2206-mediated cell death. Importantly, this work 
provides a new paradigm for MK-2206-mediated control of aberrant cell survival associated with 
IGF1R-dependent CRC that may offer new targets for enhancing cell death in cancer cells. 
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4.6 Figures 
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Figure 4.1: MK-2206 inhibits Akt signaling in IGF1R-dependent CRC cells.A) & B) Loss of 
pAkt at Ser473 and T308 on treatment with increasing concentration of MK-2206 for 72 hours in 
GEO and CBS cells respectively. GAPDH is used as a loading control. 
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Figure 4.1: 
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Figure 4.2: MK-2206 affects cell proliferation and cell death in vitro. A) MTT analysis shows 
reduction in cell proliferation on treatment with MK-2206. B) DNA fragmentation showing an 
increase in cell death with increasing concentration of MK-2206. C) Western blot analysis of 
various apoptotic members as pBad (Ser136), XIAP and Survivin. D) IP for 14-3-3 to determine 
the interaction with pBad (Ser136) and Bad showing a loss in the interaction on treatment with 
MK-2206. E) IP for Bad to determine the interaction with anti-apoptotic protein Bcl-xL.. 
(*=P<0.01 and **=P<0.001). 
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Figure 4.2: 
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Figure 4.3: MK-2206 inhibits the growth of colon tumor xenograft. A) Reduction in tumor 
size on treatment with MK-2206. B) Reduction in tumor volume in treated animals as compared 
to control animals. C) Reduction in the average tumor volume in animals treated with MK-2206 
as compared to control animals. D) Reduction in tumor weight on treatment with Akt kinase 
inhibitor. (*=P<0.01 and **=P<0.001) 
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Figure 4.3: 
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Figure 4.4: MK-2206 inhibits Akt signaling in vivo: A) IHC images showing a reduction in 
pAkt at Ser473. B) Relative quantification was performed, followed by statistical analysis to 
determine the decrease in phosphorylation of Akt at Ser473 on treatment with MK-2206. C) 
Western blot analysis to confirm the loss of pAkt at Ser473 and Thr 308 in treated animals. 
(*=P<0.01 and **=P<0.001) 
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Figure 4.4: 
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Figure 4.5: Increased cell death and decreased cell proliferation on treatment with the 
allosteric Akt kinase inhibitor: TUNEL and Ki67 IHC was performed on control and treated 
samples A) Increased cell death on treatment with the inhibitor. B) Relative quantification was 
performed followed by statistical analysis to quantify the increase in death. There was a 
significant increase in cell death in treated animals. C) Shows a loss in cell proliferation on 
treatment with MK-2206. D) Bar graphs representing a highly significant loss in Ki67 staining in 
treated animals. 
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Figure 4.5: 
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Figure 4.6: Increase in the expression of AIF on treatment with MK-2206 mediates cell 
death: A) western blot analysis showing an increase in the expression of AIF on treatment with 
MK-2206. Immunofluorescence was performed to study the translocation of AIF from 
mitochondria to the nucleus during cell death. B) Confocal images showing a reduced co-
localization of mitotracker (red) and AIF (green) in treated as compared to control cells. . 
C)Cellular fractionation to separate nucleus from cytosol was performed followed by western blot 
analysis for AIF. HDAC1 and GAPDH were used as compartmentalization control for nucleus 
and cytosol respectively. D) DNA fragmentation after treatment with AIF inhibitor results in 
reduction in cell death in presence and absence of MK-2206 thus confirming that MK-2206 
causes AIF mediated cell death. 
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Figure 4.6: 
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Figure 4.7: A) Western blot analysis showing a reduction in the expression pEzrin (T567) on 
treatment with MK-2206 in vitro. B) Treatment with MK-2206 reduces the expression of pEzrin 
(T567) in vivo.Stable knockdown of Akt2 was performed in GEO cells. C) Western blot analysis 
showing a loss of pEzrin (T567) on knockdown of Akt2. No change in total Ezrin was observed 
on loss of Akt2. D) Western blot analysis showing loss of Akt1 does not affects the expression of 
pEzrin (T567). GAPDH is used as a loading control. E) Overall mechanism for induction of cell 
death by MK-2206. Akt kinase inhibitor MK-2206 mediates cell death by two different 
mechanisms. Loss of phosphorylation of Akt results in induction and translocation of AIF from 
the mitochondria to the nucleus, where it results in DNA fragmentation. On the other hand 
treatment with MK-2206 results in loss of pEzrin (T567), which results in loss of XIAP thus 
mediating cell death. 
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Figure 4.7: 
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Supplementary Figures 
 
Figure S1: Western blot analysis showing a loss of pAkt (S473) after treatment with MK-2206 in 
HCT116 and MiaPaCa cells. 
Figure S1
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Figure S2: Transfection with siRNA for XIAP results in increase in cell death as determined by 
DNA fragmentation. 
Figure S2 
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Figure S3: Western blot analysis to determine the loss of survivin and XIAP in animals treated 
with MK-2206. 
Figure S3 
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Figure S4: There was no significant loss of body weight in mice on treatment with MK-2206.   
Figure S4 
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Figure S5: IHC images showing no change in the expression of total Akt in treated animals as 
compared to control.  
Figure S5 
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Figure S6: Relative quantification followed by statistical analysis was performed to determine 
the change in expression of total Akt. There was no significant change in the expression of total 
Akt. 
Figure S6 
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Figure S7: Eosin and Hematoxylin staining of control and treated xenograft tumors showing 
more necrosis on treatment with MK-2206. 
Figure S7 
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Figure S8: Images of control and treated animals before euthanizing. 
Figure S8 
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Figure S9: A) Western blot showing a knockdown of AIF in presence of siRNA. B) DNA 
fragmentation after knockdown of AIF shows reduction in cell death in presence and absence of 
MK-2206. 
Figure S9 
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Figure S10: No change in pEzrin (T567) and total Ezrin on knockdown of Akt3. 
Figure S10 
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Figure S11: siRNA-mediated knockdown of Ezrin showing a loss in XIAP expression.  
Figure S11 
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5. Role of Akt2 in cell survival, establishment and/or maintenance of colorectal cancer 
metastasis 
5.1 Abstract 
Akt is critical to survival signaling in various cancer types. Although it is known that Akt2 is 
responsible for establishment of CRC metastasis, the mechanism of Akt2-driven metastases is 
still not known. We show in this study that only Akt2 among Akt isoforms is required for 
metastasis. The shRNA mediated knockdown of Akt2, not Akt1, causes reduction in the 
metastatic burden in CRC. This study shows that loss of Akt2 upregulates MTSS1 (metastasis 
suppressor 1) and in parallel inhibits the expression of anti-apoptotic genes XIAP and survivin 
thus inhibiting cell survival which in turn could lead to reduction in metastatic potential of the 
cells. This study might help in understanding if loss of Akt2 could be a mechanism of increasing 
cell death thus leading to reduction in metastasis. 
5.2 Significance 
 Loss of Akt2 leads to a reduction in metastasis, identifying Akt2 as a potentially important 
therapeutic target for metastases. Strategies to inhibit Akt2 as opposed to other two isoforms may 
provide a therapeutic approach for treatment of metastases. A negative correlation between Akt2 
and MTSS1 in human primary CRC samples might be useful in identification of metastatic 
patients.  
5.3 Introduction 
The metastatic colonization of the cancer cells is the major cause of mortality in CRC patients 
(Jin, Gao et al. 2012). Significant advancements in cancer research have explained some 
mechanisms for establishment of metastasis; however, the molecular mechanisms underlying the 
maintenance of metastatic colonization are not well understood. Cancer cells have to overcome 
several barriers (matrix detachment, shear forces and resistance from the immune system) before 
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they can colonize as metastases in distant organs, thus making metastasis an inefficient process 
(Gupta and Massague 2006). Less than 1% cells of the primary tumor leave their site and survive 
in the blood circulation to reach distant organs to form metastatic colonies (Valastyan and 
Weinberg 2011). Recent studies have shown that increased cell survival is required in circulation 
as well as at the extravascular sites for metastasis of cancer cells (Eccles and Welch 2007); 
however very small populations of the cells survive and proliferate to form distant metastatic 
spots thus making “survival” a rate limiting step for metastatic colonization (Kienast, von 
Baumgarten et al. 2009). Once metastasis has occurred, there is an increase in resistance to 
apoptosis to maintain the established metastasis (Eccles and Welch 2007). It is well known that 
apoptosis is a barrier for development of cancer (Lowe, Cepero et al. 2004). Physiological stress 
stimulates a portion of  cancer cells to evade apoptosis thus allowing for progression to higher 
grade of malignancy and metastasis (Adams and Cory 2007). Cancer cells limit apoptosis by 
triggering the anti-apoptotic machinery of the cell  i.e. IAPs (Inhibitor of Apoptosis Protein 
family), members of Bcl-2 family (Bcl-xl and Mcl-1) or by inhibiting the pro-apoptotic proteins 
(Bax and Bak) (Lowe, Cepero et al. 2004), by activation of survival pathways as PI3K-Akt , or by 
upregulating MMPs or by overexpression of FAK (Townson, Naumov et al. 2003, Liotta and 
Kohn 2004, Mehlen and Puisieux 2006). According to SEER’s report for the year 2016, 20% of 
the CRC cases are diagnosed at a stage when the cancer has undergone metastasis, thus reducing 
the 5-year survival rate to 13% as compared to 91% (in case of stage I and stage II). These 
statistics suggest that it is important to identify the survival mechanisms that lead to increased 
metastasis so that they can be targeted therapeutically.  
 The PI3K-Akt signaling pathway is a downstream effector of growth factor receptors and is 
often deregulated in cancer (Fruman and Rommel 2014). Auto phosphorylation of the growth 
factor receptors leads to the synthesis of phosphotidyl inositol triphosphate (PIP3) (Vivanco and 
Sawyers 2002). Akt is a serine/threonine kinase consisting of 3 isoforms, Akt1 Akt2 and Akt3. 
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These isoforms of Akt have a high level of structural homology and share similar mechanisms of 
activation (Clark and Toker 2014). Activation of Akt is mediated by its interaction with PIP3, 
which causes a change in conformation of Akt, and its recruitment to the plasma membrane 
(Blume-Jensen and Hunter 2001), where it comes in close proximity with PDK-1 and mTORC2 
leading to phosphorylation of Akt at Thr308 and Ser473 respectively (Stokoe, Stephens et al. 
1997, Sarbassov, Guertin et al. 2005, Salmena, Carracedo et al. 2008). Akt promotes cell 
proliferation, cell survival, growth and various other signaling pathways by phosphorylating its 
downstream targets (Manning and Cantley 2007). Termination of Akt signaling is accomplished 
by multiple phosphatases including PTEN, PP2A, and PHLPP1/2 (Brognard, Sierecki et al. 2007, 
Salmena, Carracedo et al. 2008, Gewinner, Wang et al. 2009). 
 Although Akt isoforms share structural homology, phenotypes of knockout mice of 
individual Akt isoforms suggest that they have non-redundant functions (Stokoe, Stephens et al. 
1997, Cho, Mu et al. 2001, Easton, Cho et al. 2005) . Several studies have shown contradictory 
role of Akt isoforms in same cancer type as in breast cancer (Irie, Pearline et al. 2005). 
Additionally the isoforms have different roles in different cancer types (Agarwal, Brattain et al. 
2013). In breast cancer Akt1 and 2 show opposing role as Akt1 inhibits cell motility and invasion 
whereas Akt2 enhances these processes. (Irie, Pearline et al. 2005, Yoeli-Lerner, Yiu et al. 2005). 
Akt isoforms are aberrantly expressed in cancer showing heterogeneity in their expression pattern 
with overexpression of Akt1 in gastric and colon cancer. Akt2 is highly expressed in breast, 
ovarian and colon cancers and Akt3 expression increases in breast and prostate cancer. The role 
of Akt isoforms in various cancers have been discussed in detail in a review article (Agarwal, 
Brattain et al. 2013). 
 An analysis on human CRC samples showed increased expression of Akt2 in 40% of the 
tumors (Parsons, Wang et al. 2005). Previous work has shown that Akt2 is highly expressed 
during late stages of CRC and metastatic tumors. It has been demonstrated that suppression of 
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Akt2 reduces the metastasis of CRC cells which cannot be restored by overexpressing Akt1 
(Rychahou, Kang et al. 2008). Additionally, it has been reported that there is a correlation 
between PTEN deficiency, Akt2 overexpression and increased metastatic potential in CRC 
(Rychahou, Kang et al. 2008). Recent studies have shown that PTEN-deficient prostate cancer 
cells are dependent on only Akt2 for survival (Chin, Yuan et al. 2014). Genetic inactivation of 
Akt1 and Akt2 leads to reduction in proliferation in vitro and significantly reduced metastasis in 
vivo(Ericson, Gan et al. 2010). Although reports indicate the role of Akt2 in establishment of 
CRC metastasis, the mechanism of Akt2-driven metastasis is still unknown. Ingenuity pathway 
analysis (IPA) shows that there are several signaling pathways (Src, p38MAPK, Bax, ERK1/2) 
which are specifically affected  by Akt2 (Agarwal, Brattain et al. 2013) thus affecting survival of 
cancer cells.  Aberrant Akt2 activation may be playing an important role in sustaining processes 
important for metastasis. 
Metastasis Tumor Suppressor Gene 1 (MTSS1) also known as Missing in Metastasis (MIM) 
which was initially considered important for early organ development has recently been identified 
as a suppressor of metastasis of cancer cells. It is known to affect actin assembly thus inhibiting 
cell growth and cell migration. It has been reported that MTSS1 expression decreases in various 
cancers such as breast, esophageal, bladder, kidney, gastric and pancreatic cancer (Du, Ye et al. 
2011, Wang, Xu et al. 2011, Xie, Ye et al. 2011, Du, Ye et al. 2013, Zhou, Li et al. 2015). 
MTSS1 interacts with an actin-binding protein, Cortactin, to mediate its action. Cortactin is a 
nucleation-promoting factor, which gets activated on binding with MIM-B (Lin, Liu et al. 2005). 
It is responsible for formation of lamellipodia by enhancing the formation of branched actin 
network. 
Although it is known that Akt2 overexpression is required for establishment of metastasis, 
not much is known about the role of Akt2 in maintenance of established metastasis in colorectal 
cancer. Moreover, it is not known whether Akt2 provides a survival advantage to the cells after 
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establishment of metastasis. To investigate the role of Akt isoforms in maintenance of established 
metastasis we have used lentiviral doxycycline inducible knockdown of Akt isoforms (in vitro), 
an orthotopic implantation model for in vivo studies, and data from The Cancer Genome Atlas for 
information about CRC patients. We have demonstrated an increase in the expression of MTSS1 
on loss of Akt2; however, loss of Akt1 and Akt3 did not show any such effect. Furthermore, for 
in vivo studies, the effect of loss of Akt2 on established metastases was determined by 
introducing Dox in the drinking water after metastases was established. This was done to 
determine whether Akt2 loss impacts the maintenance of established metastases. It was observed 
that loss of only Akt2 efficiently reduced the metastatic burden. These data help us to postulate 
that specific reduction of Akt2 could be a means of enhancing cell death, thus leading to reduced 
survival in established metastasis.    
5.4 Results 
5.4.1 Knockdown of Akt isoforms affect cell proliferation and cell death in highly metastatic 
colon cancer cells 
To understand the role of Akt isoform on cell proliferation and cell death, we have established 
doxycycline (Dox)-inducible knockdown of the isoforms in GEO and CBS cells which express 
high levels of all the three Akt isoforms (Fig.5.1 A) . Non-targeting sh was used as the control. 
We observed no change in the expression of Akt isoforms on treatment with Dox in non-targeting 
sh (Fig.S1 A, B). GEO and CBS cells are IGF1R (Insulin like growth factor 1 receptor) 
dependent cell lines. It is known that 30-40% cases of CRC are IFG1R-dependent, thus making 
these cells a suitable model for this study. Figure5.1 (B, C, D and E) show that addition of Dox 
leads to loss of Akt2 both at the protein and RNA levels. The shRNA for Akt2 is specific to the 
respective gene as there is no change in the expression of Akt1 and Akt3 on knockdown of Akt2. 
To determine the effect of Akt2 on cell growth, MTT assays were performed after treatment with 
Dox. There was a significant (p<0.001) reduction in cell proliferation on loss of Akt2 in 
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comparison to non-targeting sh. (Fig.5.1 F, G). Additionally we observed that Akt2 knockdown 
results in about a 6-fold increase in cell death as determined by DNA fragmentation assay 
(Fig.5.1 H, I) in comparison to non-targeting sh +Dox. Fig. S2,S3 (E, F) show that there was no 
change in cell proliferation on loss of Akt1 and Akt3 respectively, however a two fold increase in 
cell death was observed on loss of Akt1 and Akt3 (Fig.S2,S3 (G, H)) respectively.  
5.4.2 Effect of Akt isoforms on motility of colon cancer cells  
We performed transwell migration assays on GEO GFP Akt isoform knockdown cells to 
determine the effect of Akt isoforms on motility. We observed that there is a highly significant 
(about 75% reduction) reduction in motility after knockdown of Akt2 (Fig.5.1 J, K). A reduction 
in cell motility on loss of Akt1 and Akt3 was also observed, although to a much lesser extent 
(about 35% reduction) (Fig. S2,S3 (I, J)). Non-targeting sh was used as a control. 
5.4.3 Regulation of cell survival by Akt isoforms 
The Inhibitor of Apoptosis Protein (IAP) family members are aberrantly expressed in various 
cancers (Berezovskaya, Schimmer et al. 2005). The members of IAP family, XIAP (X-linked 
IAP) and survivin are usually present in mitochondria. Under stress conditions, XIAP and 
survivin move into the cytoplasm where they form a complex which then stabilizes the IAP 
members leading to increased cell survival (Dohi, Okada et al. 2004). Additionally, Akt 
phosphorylates XIAP at serine 87 resulting in its stabilization (Dan, Sun et al. 2004), thereby 
leading to increased survival. Loss of Akt isoforms leads to reduction in the expression of both 
XIAP and survivin (Fig.5.2 A, B: Fig. S4,S5 (A, B)). Additionally we observed an increase in the 
expression of Apoptosis Inducing Factor (AIF) on loss of Akt1 and Akt2 (Fig.5.2 A, Fig.S4 (A, 
B)). Previous studies have shown that loss of pAkt in the presence of an Akt kinase inhibitor, 
MK-2206, leads to an increase in the expression of AIF (Agarwal, Chaudhuri et al. 2014). AIF is 
normally present in the mitochondria but upon induction of apoptosis this protein translocates 
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from mitochondria to nucleus and causes DNA fragmentation. Treatment with MK-2206 leads to 
translocation of AIF into the nucleus thus leading to increased cell death (Agarwal, Chaudhuri et 
al. 2014). Additionally loss of Akt2 reduces the phosphorylation of the cytoskeletal protein ezrin 
(T567), which then inhibits cell survival. Loss of Akt1 and Akt3 do not affect the 
phosphorylation of ezrin. We observed no change in the expression of XIAP, survivin, AIF, ezrin 
and pEzrin (T567) on treatment with Dox of GEO and CBS cells expressing non-targeting sh 
(Fig.S1 C, D) 
5.4.4 Differential regulation of MTSS1 by Akt isoforms  
The differential effect of Akt isoforms on metastatic genes was determined by performing a RT
2 
Profiler PCR array analysis on human metastatic genes. We observed that there was differential 
expression of several metastatic genes on loss of the Akt isoforms (Fig.5.3 A). Loss of Akt2 led 
to an increase in the expression of MCAMs, Kiss1 and E-Cadherin. The role of these proteins on 
metastasis has been well studied (Cheng, Chan et al. 2007, Navenot, Fujii et al. 2009, Williams, 
Schneider et al. 2014). However, we identified a novel protein, Metastasis Suppressor Gene 1 
(MTSS1), which was differentially expressed on loss of Akt isoforms. We observed that there 
was a robust increase in the expression of MTSS1 on loss of Akt2 (Fig.5.3 B, C), however, loss 
of Akt1 and Akt3 did not affect its expression (Fig.S4,S5 (C, D)).  MTSS1 has been identified as 
a potential anti-metastatic protein as its expression is less in metastatic cells compared to non-
metastatic cancer cells in several types of malignancies, including  prostate, stomach, bladder and 
liver cancer  (Parr and Jiang 2009), (Lee, Macoska et al. 2002). Contradictory reports suggest that 
MTSS1 over expression increases the metastatic potential of the melanoma cells (Mertz, Pathria 
et al. 2014). MTSS1 is still understudied in CRC. Bompard et.al. have shown that MTSS1 affects 
cytoskeleton dynamics by interacting with cortactin (CTTN), a substrate of Src kinase and major 
activator of actin- branching and polymerization (Bompard, Sharp et al. 2005). We made the 
observation that only Akt2 depletion increases the expression of MTSS1 and reduces the 
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expression of pSrc (Y416) and pCortactin (Y421) (Fig.5.3 B, C). MTSS1 has been shown to 
interact with protein tyrosine receptor phosphatase delta, and leads to its increased expression, 
which in turn inhibits the phosphorylation of Src. We observed a loss in the expression of pSrc 
(Y416) and pCortactin (Y421) on knockdown of Akt2. However, no change in the expression of 
pSrc and pCortactin was observed on loss of Akt1 and Akt3 (Fig.S3, S4 (C, D)).  
The expression of MTSS1 is regulated by DNA promoter methylation (Fan, Chen et al. 
2011), ubiquitination (Zhong, Shaik et al. 2013) and/or by miRNAs (Guo, Ren et al. 2015). 
Methylation pyrosequencing was performed (-141 to -236 upstream of the transcription start site) 
and CpG methylation percentage was aligned with Human Genome build Dec. 2013 
(GRCh38/hg38) to determine the percentage of methylation as indicated in Supplementary table1. 
We observed no change in the percentage of MTSS1 promoter methylation on loss of any of the 
isoforms (Supplementary table1). β-TRCP is an E3 ubiquitin ligase, which causes the 
ubiquitination of MTSS1 thus leading to its proteasomal degradation (Zhong, Shaik et al. 2013). 
Interestingly, we observed a robust loss in the expression of β-TRCP on loss of Akt2 with no 
change in the expression on loss of Akt1 and Akt3 (Fig.5.3 G, Fig.S4,S5 (E)) , thus suggesting 
that loss of Akt2 leads to less ubiquitination and less degradation of MTSS1, resulting in a 
increase in its expression. 
MTSS1 affects the motility of cells by affecting the actin cytoskeleton (Bompard, Sharp 
et al. 2005). To confirm that the reduction in motility of CRC cells by Akt2 loss is driven by 
MTSS1, we knocked down MTSS1 in GEO GFP Akt2 knockdown cells. We observed that loss in 
MTSS1 generates increased expression of pSrc and pCortactin (Fig.5.3 E). Transwell migration 
assay showed that there was a 55% increase in the motility of the cells on loss of MTSS1 as 
compared to Akt2 sh +Dox (Fig.5.3 F). Additionally, we determined the effect of MTSS1 loss on 
the actin cytoskeleton by performing immunofluorescence staining with Phalloidin antibody. 
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Fig.S6 shows that there is more actin polymerization (as can be seen by higher phalloidin 
staining) on loss of MTSS1 thus leading to increase in the motility of the cells. 
5.4.5 Regulation of metastasis by Akt isoforms in vivo 
Orthotopic implantation studies were performed with Akt1 sh and Akt2 sh to determine the effect 
of Akt isoform on metastasis. Akt isoforms were knocked down by adding Dox to the drinking 
water. The sh was induced after six weeks of caecal implantation of the tumor, thus allowing 
establishment of primary tumor and metastases. This strategy is designed to determine the effect 
of Akt isoforms on maintenance of established metastasis. Non-targeting sh was used as a control. 
We observed that 59% of animals had liver metastasis in non-targeting sh +Dox, 52% of animals 
had metastasis in Akt1 sh +Dox (Fig.S7 B), however only 35% of animals in Akt2 sh +Dox had 
metastasis (Fig.5.4 B).  Importantly, no change in the weight of primary tumor was observed on 
loss of Akt1 (Fig.S7 C) and Akt2 (Fig.5.4 C) indicating that primary tumor burden remains 
unchanged. Expression of human GAPDH was determined in the mice liver on loss of Akt1 and 
Akt2 to determine the metastatic tumor burden. There was a significant reduction in metastatic 
burden on loss of Akt2 as compared to non-targeting sh +Dox (Fig.5.4 D), however the metastatic 
burden on loss of Akt1 did not change significantly in comparison to non-targeting sh +Dox 
(Fig.S7 D). Furthermore hematoxylin and eosin staining shows less metastatic areas in the liver 
after loss of Akt2 (Fig.5.5 A) as compared to non-targeting sh +Dox and Akt1 sh +Dox (Fig.S8 
A). To quantify metastatic spots we counted the RFP spots on each lobe of the liver under 
immunofluorescence microscope. Fig.5.5 B shows the representative images of liver metastatic 
spots as observed in Akt2sh +Dox and non-targeting sh +Dox. Fig.5.5 C represents the 
quantification of the metastatic spots. (Each dot on the graph is a representation of one mouse). 
There was a significant reduction in the number of metastatic spots in Akt2 sh +Dox as compared 
to non-targeting sh +Dox. However loss of Akt1 did not result in significant change in liver 
metastatic spots as shown in Fig.S8 C. 
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5.4.6 Regulation of cell survival by Akt isoforms in vivo 
TUNEL staining of primary tumors showed that there was an increase in the number of apoptotic 
cells after knockdown of Akt isoforms. We observed a six-fold increase in the % of apoptotic 
cells on loss of Akt2 (Fig.5.6 A, B) and a two-fold increase on loss of Akt1 (Fig.S9 A, B) in 
comparison to non-targeting sh +Dox. Additionally there was strong nuclear staining for Ki67 in 
non-targeting sh +Dox. Quantitative analysis by Definience Tissue Studies 64 (Dual 4.1) software 
revealed that there was a significant reduction (p<0.001) in Ki67 staining intensity on loss of 
Akt2 (Fig.5.6 C, D). Akt1 knockdown showed significant reduction (p<0.05) in Ki67 staining 
intensity as compared to non-targeting sh +Dox (Fig.S9 (C, D)). Additionally, IHC analysis 
reveals loss of Akt1 and Akt2 in the primary tumor as shown in Fig.S9 E, F and Fig.5.6 E,F 
respectively. These data suggest that introduction of Dox led to a reduction in expression of Akt 1 
and Akt2 in the primary tumor leading to an increase in apoptosis as shown by increased TUNEL 
staining. However, due to inter-tumor and intra-tumor heterogeneity there was no significant 
change in the overall primary tumor burden, which is represented by no significant change in the 
weight of the primary tumor.  
Next we performed IHC analysis for MTSS1 on primary tumor samples. We observed 
strong staining of MTSS1 in Akt2 knockdown primary tumor samples as compared to Akt1sh 
+Dox and non-targeting sh +Dox. Quantitative analysis reveals, that, in comparison to non-
targeting sh +Dox, Akt2 knockdown results in a significant (p<0.001) increase in the staining 
intensity of MTSS1 (Fig.5.6 G, H). There was no significant difference in the staining intensity of 
MTSS1 in Akt1 shRNA primary tumor samples (Fig.S9 (G, H). Additionally it was observed that 
there was a loss in the expression of the IAP family member XIAP on loss of Akt 1 and Akt2. 
Fig.5.6 I and Fig.S9 I showed strong nuclear and cytoplasmic staining of XIAP in non-targeting 
sh +Dox. Quantitative analysis revealed that there was a significant reduction (p<0.001) in the 
staining intensity for XIAP on loss of Akt1 and Akt2 (Fig.S9 J and Fig.5.6 J).  
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Western blot analysis was performed on the primary tumor samples to confirm the IHC 
results. We observed a decrease in the expression of β-TRCP on loss of Akt2 (Fig.5.6 K) in the 
primary tumor, with no change on loss of Akt1 (Fig.S9 K), which suggests less ubiquitin-
mediated degradation of MTSS1 on loss of Akt2, corroborating our in vitro data. 
5.4.7 Expression of Akt isoforms and MTSS1 in human CRC samples 
The Cancer Genome Atlas data sets showed that there was a significant increase (p<0.0001) in 
Akt2 in tumor samples in comparison to normal samples, however the expression levels of Akt1, 
Akt3 and MTSS1 were reduced significantly in tumor samples (Fig.5.7 A). Additionally we 
observed that there was a negative correlation between Akt2 and MTSS1 in primary human tumor 
samples as seen in the scatter plot (Fig.5.7 B). Furthermore, Oncomine data also showed that 
Akt2 and MTSS1 are negatively correlated. There was an increase in the expression of Akt2 as 
colon cancer progresses in comparison to normal colon although a decrease in the expression of 
MTSS1 was observed in the matched samples. 
5.5 Discussion 
CRC is the second leading cause of cancer related deaths in the United States. Advances in CRC 
screening, early detection, prevention and research during past few decades have significantly 
increased the 5-year survival rate.  However, the survival rate has continued to show dismal 
progress in the metastatic stage of the disease. The higher survival rate at early stage is attributed 
to surgical resection of primary tumor followed by adjuvant chemotherapy, however metastasis is 
untreatable (Jin and Mu 2015) thus emphasizing the urgent need to develop anti-metastatic 
therapies . There are several molecular pathways that lead to increased proliferation/survival at 
primary as well as metastatic sites (Valastyan and Weinberg 2011). Anti-metastatic therapies 
might be more effective if they inhibit the survival of the cancer cells which have already spread 
out from the primary tumor instead of targeting the escape of cells from the primary tumor 
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(Valastyan and Weinberg 2011). This is important because by the time the patient is diagnosed 
with tumor, the cancer cells have already left the primary tumor (Valastyan and Weinberg 2011) 
and are either at the step of intravasation, circulation or extravasation of metastasis. It has been 
reported that drugs targeting metastasis have to be used for long term, thus making them 
incompetent in the clinic due to their known side effects (Valastyan and Weinberg 2011). Thus, 
anti-metastatic therapies need to be designed in such a way that they elicit regression of 
established metastasis so that they can qualify for clinical practice. 
To determine the effect of a critical survival node “Akt” in metastasis, various studies 
have been performed. Rychahou et.al.have shown that suppression of Akt2 reduces the metastatic 
potential of CRC cells both in vitro and in vivo. Furthermore, they have also reported a link 
between PTEN loss, Akt2 overexpression and increased metastatic efficiency of CRC cells 
(Rychahou, Kang et al. 2008).  Ericson et.al.reported that genetic loss of Akt1, Akt2 and PDPK1 
inhibit the growth of CRC cells (Ericson, Gan et al. 2010). These studies confirmed that loss of 
Akt2 leads to reduction in the establishment of metastasis however mechanism for reduction in 
metastasis on loss of Akt2 were not well characterized. Splenic injections of CRC cells were 
performed to determine the effect of Akt2 on metastasis in these studies. The limitation of this 
model is that it does not mimic the natural pattern of CRC metastasis. In this method, the earlier 
steps of metastasis (invasion and intravasation) are bypassed and only later stages of metastasis 
(circulation and extravasation) can be studied. The orthotopic implantation model used in the 
present study recapitulates the pattern of human CRC primary and metastatic deposits as it 
addresses both the early stages i.e. local invasion at the primary site as well as the later stages of 
metastasis. Although no change in primary tumor burden was observed on loss of Akt2, we 
observed  40% reduction (6 animals out of 17) in the number of animals with liver metastasis on 
loss of Akt2, demonstrating that loss of Akt2 might play a role in regression of established CRC 
metastasis. It is known that 20% of the cases of CRC are diagnosed at stage 3 or stage 4 i.e. when 
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cancer has already undergone metastasis. Identification and genetic validation of the role of Akt2 
in the maintenance of established metastasis provides insight for inhibiting Akt2 for CRC patients 
with metastasis. 
Mechanistically we identified that loss of Akt2 leads to decrease in the expression of 
IAPs such as XIAP and survivin, leading to increase in cell death. Shiue et.al.have shown that 
Akt2 is responsible for the phosphorylation of ezrin at T567, thus leading to its activation, which 
in turn leads to increase in metastasis (Shiue, Musch et al. 2005). Additionally, it has been shown 
that phosphorylated ezrin (T567) increases cell survival by increasing the expression of XIAP. 
We observed a decrease in the phosphorylation of ezrin (T567) on loss of Akt2. Loss of Akt2 led 
to an increase in the expression of Apoptosis Inducing Factor (AIF). AIF is responsible for DNA 
fragmentation thus leading to cell death (Agarwal, Chaudhuri et al. 2014).  
Importantly an increase in the expression of MTSS1 was observed on loss of Akt2. It has 
been reported that loss of MTSS1 promotes tumor growth by enhancing cell proliferation, 
invasion and/or cell migration (Fan, Chen et al.), (Parr and Jiang 2009), (Loberg, Neeley et al. 
2005). MTSS1 leads to a reduction in the expression of pSrc at Y416 by activating PTP δ (Protein 
Tyrosine Phosphatase δ), which in turn leads to loss in the phosphorylation of Cortactin at 
Tyrosine 421, thus affecting the actin cytoskeleton (Bershteyn, Atwood et al. 2010). Interestingly, 
we observed that loss of Akt2 leads to the activation of MTSS1pSrcpCortactin axis leading 
to reduction in metastasis (Fig.5.7 C). MTSS1 is regulated by methylation (Utikal, Gratchev et al. 
2006) and/or ubiquitination (Zhong, Shaik et al. 2013) . β-TRCP is a ubiquitin ligase enzyme that 
ubiquitinates MTSS1 thus leading to its degradation via 26S proteasome (Fuchs, Spiegelman et 
al. 2004). MTSS1 expression is inhibited by methylation of the CpG Island in its native promoter 
region (Utikal, Gratchev et al. 2006). We observed that loss of Akt2 does not affect the 
methylation status of MTSS1 (Supplementary table 1). However there was a decrease in the 
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expression of β-TRCP on loss of Akt2. This might indicate less ubiquitin-mediated degradation 
of MTSS1 leading to an increase in its expression. Loss of Akt1 and Akt3 does not show any 
change in the expression of β-TRCP leading to no reduction in the expression of MTSS1. 
 TCGA data analysis pointed out Akt2 as the only isoform which is significantly increased 
(p<0.0001) in CRC tumor samples as compared to normal samples, whereas Akt1, Akt3 and were 
significantly reduced.  Interestingly, it was also observed that in primary tumor, Akt2 and MTSS1 
are negatively correlated (r= -0.12). These data help us to hypothesize that Akt2/MTSS1 negative 
correlation might be useful in identification of patients with metastasis. This would need to be 
confirmed by performing analysis on larger sets of human samples. This study as well as the 
earlier reports on the role of Akt2 in metastasis emphasizes that Akt2-specific inhibitors can be 
used as a targeted therapy for metastatic patients. 
 Overall we have demonstrated that out of the three isoforms of Akt, Akt2 and its 
downstream signaling plays a critical role in mediating cell survival and maintenance of CRC 
metastasis, thus identifying Akt2 as an important therapeutic target. The translational importance 
of determining the effect of Akt2 on established metastasis needs to be clinically evaluated in the 
future. 
5.6 Figures
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Figure 5.1: (A) Western blot analysis to show the endogenous level of Akt1, 2 and 3 in colon 
cancer cells. (B) and (C) Immunoblot showing knockdown of Akt2 in presence of Dox in GEO 
and CBS cells respectively. The blot represents that the shRNA is specific to Akt2 as there is no 
change in the expression of Akt1 and Akt3 in the presence of Dox. GAPDH is used as a loading 
control.  (D) and (E) qPCR analysis indicates that there is a significant loss of Akt2 on treatment 
with Dox in both GEO and CBS cells respectively. (F) and (G) demonstrate that there is a 
significant loss in cell proliferation on loss of Akt2 in comparison to non-targeting sh+Dox as 
determined by MTT assay. (H) and (I) DNA fragmentation assay reveal that there is 5-6 fold 
increase in cell death on removal of Akt2 in both GEO and CBS cell lines. (J) Representative 
images depicting less migration of cells on loss of Akt2. (K) Quantification of transwell 
migration assay showing a significant reduction in motility of cells on loss of Akt2. 
(***=p<0.0001) 
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Figure 5.2: (A) and (B) Western blot analysis shows a robust loss in the expression of XIAP and 
Survivin on loss of Akt2. There is an increase in the expression of AIF and a decrease in the 
expression of pEzrin (T567) on knockdown of Akt2 in GEO and CBS respectively. However 
there is no change in the expression of total ezrin. GAPDH has been used as a loading control.  
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Figure 5.3: (A) Venn diagram showing the genes which were differentially expressed on 
knockdown of the three Akt isoforms. The genes in Red have higher expression as compared to 
non-targeting sh and the genes in green color have reduced expression. (B) and (C)  Western blot 
showing an increase in the expression of MTSS1 and a loss in the expression of pSrc (Y416) and 
pCortactin (Y421) on removal of Akt2 in GEO and CBS cells respectively. The expression of 
total Src remains unchanged. (D) Immunoblot showing a knockdown on MTSS1 in Akt2 
knockdown cells. (E) Demonstrates a loss in the expression of pSrc (Y416) and pCortactin 
(Y421) on loss of Akt2, this loss is rescued when MTSS1 was knocked down in Akt2 sh +Dox 
cells. (F) Representative images of transwell migration assay showing a reduction in migration of 
cells on loss of Akt2, however MTSS1 knockdown leads to increase in the motility of the cells. 
(G) Quantification of migration assay shows a significant reduction in cell motility on loss of 
Akt2, which is rescued on loss of MTSS1. (H) Western blot analysis shows that there is a loss in 
the expression of βTRCP on loss of Akt2. 
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Figure 5.3: 
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Figure 5.4: (A)Fluorescent image of whole mice, primary tumor, liver, lung from orthotopic 
implantation of non-targeting sh and Akt2 sh xenograft tumor respectively. (B) showing that there 
is a 40% reduction in the number of animals with metastasis on loss of Akt2 in comparison to 
non-targeting sh. (C) Bar graph showing no change in the weight of primary tumor on loss of 
Akt2. (D) qPCR analysis shows a reduction in the expression of human GAPDH in mice liver 
with Akt2 sh tumor , thus showing a reduction in metastatic tumor burden. 
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Figure 5.4: 
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Figure 5.5: (A) H and E staining of the primary tumor and liver metastasis samples. (B) 
Representative images of liver metastatic spots as seen under immunofluorescence microscope. 
(C) Quantification of the number of liver metastatic spots, showing a significant (p<0.05) 
reduction in the number of metastatic spots on loss of Akt2. 
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Figure 5.5: 
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Figure 5.6:(A) TUNEL staining of the primary tumor. The brown staining represents the 
apoptotic cells. (B) Statistical analysis shows that there is a highly significant (p<0.001) increase 
in the % of apoptotic cells on loss of Akt2. (C) Ki67 staining for Akt2 sh +Dox and non-targeting 
sh +Dox. (D) Bar graphs show that there is a highly significant (p<0.001) decrease in the staining 
intensity of Ki67 on loss of Akt2. (E) IHC analysis showing a loss in expression of Akt2 in the 
primary tumor in presence of Akt2sh. (F) Quantitative representation shows that there is a 
significant reduction (P<0.001) in the staining intensity of Akt2 in Akt2sh tumors as compared to 
tumors with non-targeting sh. (G) IHC staining shows that there is a robust increase in the 
expression of MTSS1 on loss of Akt2 as compared to non-targeting sh +Dox. (H) Bar Graphs 
show that there is a significant increase (P<0.001) in the expression of MTSS1 on loss of Akt2. 
(I) demonstrates the expression of XIAP on loss of Akt2. (J) Bar graphs show a significant 
reduction (p<0.001) in the staining intensity of XIAP on loss of Akt2 as compared to non-
targeting sh. (K) Western blot analysis of primary tumor showing a reduction in the expression of 
XIAP and β-TRCP and an increase in the expression of MTSS1 on loss of Akt2.  
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Figure 5.6: 
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Figure 5.7:(A)shows the differential expression of Akt1, 2, 3 and MTSS1 in normal and CRC 
tumor samples. There is a significant increase in the expression of Akt2 in tumor samples as 
compared to normal. (B)Scatter plot showing a negative correlation between Akt2 and MTSS1. 
The Pearson correlation coefficient (r= -0.12). The negative correlation is significant (p=0.04). 
(C) Proposed mechanism for reduction in cell survival and cell motility on loss of Akt2 in CRC 
cells. 
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Figure 5.7: 
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Figure S1:(A) and (B) Western blot analysis shows no change in the expression of Akt1, 2 and 
Akt3 on treatment with Dox in non-targeting sh in GEO and CBS cells respectively. (C) and (D) 
demonstrates no change in the expression of XIAP, survivin, AIF, ezrin and p ezrin (T567) in 
non-targeting sh on treatment with Dox in GEO and CBS cells respectively. 
Figure S1: 
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Figure S2: (A) and (B) Western blot analysis showing knockdown of Akt1 in presence of Dox in 
GEO and CBS cells respectively. There is no change in the expression of Akt2 and Akt3 on loss 
of Akt1, suggesting that the shRNA is specific to Akt1. GAPDH is used as a loading control. (C) 
and (D) qPCR analysis demonstrates a significant (p<0.001) of Akt1 when the cells are treated 
with Dox in both  GEO and CBS cells respectively. (E) and (F) MTT assay shows that there is no 
significant change in cell proliferation on loss of Akt1 in comparison to non-targeting sh +Dox. 
(G) and (H) show that there is about 2-3 fold increase in cell death on loss of Akt1 as determined 
by DNA fragmentation assay in GEO and CBS cells.(I) Representative images showing reduction 
in motility of the cells on loss of Akt1. (J) Bar graphs show that there is about a 50% reduction in 
cell motility on loss of Akt1. 
Figure S2: 
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Figure S3: (A) and (B) Western blot analysis shows that there is a loss of Akt3 in the cells 
transfected with Akt3 sh and treated with Dox in GEO and CBS cells respectively. The shRNA is 
specific to Akt3 as there is no change in the expression of Akt1 and Akt2 when Akt3 is knocked 
down. (C) and (D) shows that there is a significant (p<0.01) loss in the expression of Akt3 at 
RNA level on treatment with Dox in both GEO and CBS respectively. (E) and (F) MTT assay 
shows that there is no change in the proliferation of cells on loss of Akt3 in comparison to non-
targeting sh +Dox in GEO and CBS cells respectively. (G) and (H) Loss of Akt3 leads to about a 
two fold increase in cell death as determined by DNA fragmentation assay in GEO and CBS cells 
respectively. (I) Representative images of transwell migration assay showing a reduction in cell 
motility on loss of Akt3. (J) Bar graph shows that there is a 50% reduction in the motility of the 
cells on loss of Akt3.  
Figure S3: 
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Figure S4: (A) and (B) Western blot analysis shows that there is a loss in the expression of XIAP 
and survivin on loss of Akt1 in both GEO and CBS cells respectively. Removal of Akt1 leads to 
an increase in the expression AIF, however there is no change in the expression of ezrin and p 
ezrin (T567). (C) and (D) A loss in the expression of MTSS1 on knockdown of Akt1 in GEO and 
CBS respectively. There is no change in the expression of total Src and pCortactin (Y421), 
however there is an increase in the expression of pSrc (Y416) on loss of Akt1 in GEO and CBS 
cells respectively. (E) Shows no change in the expression of β-TRCP on loss of Akt1.  
Figure S4: 
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Figure S5: (A) and (B) shows loss in XIAP, survivin and AIF on knockdown of Akt3 in both 
GEO and CBS cells. (C) and (D)  represents reduction in the expression of MTSS1 on loss of 
Akt3 in GEO and CBS respectively. There is no change in the expression of total Src, pSrc 
(Y416) and pCortactin (Y421) on loss of Akt3 in GEO and CBS cells respectively. (E) 
Demonstrates no change in the expression of βTRCP on loss of Akt3. 
Figure S5: 
 
 
 
161 
 
 
Figure S6: (A) Representative images of immunofluorescence with antibody for phalloidin (far 
red) and DNA (blue). Scale bar is 10μm. 
Figure S6: 
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Figure S7: (A) Fluorescent image of whole mice, primary tumor, liver, lung from orthotopic 
implantation of non-targeting sh and Akt1 sh xenograft tumor respectively. (B) Shows no 
significant change in the number of animals with metastasis on loss of Akt1 in comparison to 
non-targeting sh +Dox. (C) Bar graph shows that there is no significant change in the weight of 
primary tumor. (D) Bar graphs show that there is no significant change in the expression of 
human GAPDH in the mice liver on loss of Akt1. 
Figure S7: 
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Figure S8: (A)H and E staining of the primary tumor and liver metastasis samples on loss of 
Akt1.(B) Representative images of liver metastatic spots as seen under immunofluorescence 
microscope. (C) Quantification of the number of liver metastatic spots, showing no change in the 
number of metastatic spots on loss of Akt1. 
Figure S8: 
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Figure.S9:(A) TUNEL staining of the primary tumor. The brown staining represents the 
apoptotic cells. (B) Statistical analysis shows that there is a significant (p<0.01) increase in the % 
of apoptotic cells on loss of Akt1. (C) Ki67 staining for Akt1 sh +Dox and non-targeting sh 
+Dox. (D) Bar graphs show that there is a significant (p<0.01) decrease in the staining intensity 
of Ki67 on loss of Akt1.(E) IHC analysis showing a loss in expression of Akt1 in the primary 
tumor in presence of Akt1sh. (F) Quantitative representation shows that there is a significant 
reduction (p<0.001) in the staining intensity of Akt1 in Akt1sh +Dox tumors as compared to 
tumors with non-targeting sh +Dox. (G) IHC staining shows that there is no change in the 
expression of MTSS1 on loss of Akt1 as compared to non-targeting sh +Dox. (H) Bar Graphs 
show there is no significant change in the expression of MTSS1 on loss of Akt1. (I) demonstrates 
expression of XIAP on loss of Akt1. (J) Bar graphs show a significant reduction (p<0.001) in the 
staining intensity of XIAP on loss of Akt1 as compared to non-Targeting sh +Dox. (K) Western 
blot analysis on primary tumor for XIAP, MTSS1 and β-TRCP on loss of Akt1. 
Figure.S9: 
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Supplementarytable 1shows the pyrosequencing data to determine the status of methylation of 
MTSS1 on loss of Akt isoforms.The percent methylation values that hover around 40-50% are 
suggestive of one allele being methylated (not expressed) and the other allele being of low 
methylation (possibly expressed).  
Supplementarytable1 
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Supplementary table 2: List of antibodies used  
 
Antibody 
 
Source Cat# Dilution 
Apoptosis Inducing Factor Cell Signaling 4642 1:1000 
Akt1 (Western blot) Cell Signaling 2967 
1:1000 
 
Akt1 (IHC) Cell Signaling 2938 
1:50 
 
Akt2 (Western blot) Cell Signaling 5239 
1:1000 
 
Akt2 (IHC) Santa Cruz 5270 
1:500 
 
Akt3 Cell Signaling 4059 
1:1000 
 
β-TRCP Cell Signaling 4394 
1:1000 
 
Ezrin Santa Cruz 71082 
1:1000 
 
Ki67 (IHC) BD Biosciences 550609 
1:100 
 
MTSS1 (Western blot) Cell Signaling 4385 
1:1000 
 
MTSS1 (IHC) Santa Cruz 101204 
1:50 
 
pCortactin (Y421) Cell Signaling 4569 
1:1000 
 
pEzrin (T567) Cell Signaling 3149 
1:1000 
 
pSrc (Y416) Cell Signaling 6943 
1:1000 
 
Survivin Cell Signaling 2803 
1:1000 
 
Total Src Cell Signaling 2108 
1:1000 
 
XIAP (Western blot) Cell Signaling 14334 
1:1000 
 
XIAP (IHC) Cell Signaling 14334 
1:10 
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Chapter VI 
Summary and Future Directions 
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6. Summary and future directions 
6.1 Central theme and therapeutic approach 
The central theme of the dissertation is to identify molecules to develop novel therapies directed 
to target maintenance of established CRC metastasis. It is known that altered expression of Akt 
isoforms affects the functional characteristics of cancer cells. To clearly understand the effect of 
Akt activation and Akt isoform expression on colon cancer metastasis, we have utilized kinase 
inhibitor of Akt for in vitro and in vivo studies. Additionally we have also developed inducible 
knockdown of Akt isoforms to determine the role the isoforms on CRC cells and specific 
inhibitors targeted to the isoforms can be designed. Although a lot of work has been done 
previously to understand the role of Akt isoforms on metastasis, the mechanisms accounting for 
alteration in metastatic potential of the cells is still unknown. 
6.1.1 Current standing 
We and others have identified that pAkt can be an important target in multiple cancer types. 
There are several Akt kinase inhibitors which have used in the past as perifosine, deguelin, 
A443654 and Akti1/2, GSK690693 and HSP90 inhibitors. These inhibitors have failed in clinical 
research due to their non-specificity and/or due to their toxic side-effects. We have utilized MK-
2206 to inhibit the phosphorylation of Akt. In the current in vitro studies we have demonstrated 
that loss of pAkt on treatment with MK-2206 leads to a reduction in expression of XIAP and 
survivin. Additionally, it has been also observed that there is an increase in the expression of 
Apoptosis Inducing Factor (AIF) which is responsible for caspase-independent cell death. Thus 
loss of pAkt leads to a dual mechanism of cell death in colon cancer cells.  We also performed in 
vivo studies to determine the effect of MK-2206 on xenograft tumor formation. Treatment with 
MK-2206 led to a robust reduction on the formation of xenograft. We observed a significant 
reduction in tumor volume and tumor weight, however there was no change in the mice weight 
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suggesting that the drug did not have any side effects on mice. Thus our in vitro data corroborated 
the in vivo data. Thus this study led to the identification of MK-2206 as an anti-tumorigenic agent 
in CRC. 
6.1.2 Future directions 
The next step for this study would be to identify the effect of MK-2206 on metastasis.  It would 
be important to determine whether MK-2206 affects the growth of primary tumor and /or the 
formation of liver and lung metastases. Additionally we would determine if loss of pAkt affects 
the establishment of metastasis or maintenance of established metastasis. This would help to 
determine the stage of CRC at which MK-2206 can be tested in patients.  
Previous studies have used MK-2206 in combination with chemotherapeutic agents 
including docetaxel, paclitaxel, carboplatin, gemcitabine, 5-fluorouracil (5-FU), doxorubicin, 
camptothecin, RTK inhibitors such as lapatinib and erlotinib, and EGFR and IGFR inhibitors. An 
in vitro study would be carried out with combination of MK-2206 and chemotherapeutics to 
determine whether these combination studies show syngeneic effect and further increase cell 
death. If we observe a synergistic effect on our cell models, in vivo studies would be performed 
with the combination of MK-2206 and chemotherapeutic agents. 
6.2 Potential therapy against metastasis 
The metastatic colonization of tumor cells is the major cause of CRC-related deaths in the United 
States. Cancer cells overcome several barriers before they can establish and colonize, thus 
making metastasis an inefficient process. Recently it has been shown that very small population 
of cells survive and proliferate to form distant metastatic spots, thus making survival a rate-
limiting step for metastasis. Once metastasis occurs, there is an increase in resistance to apoptosis 
to maintain the established metastasis.  
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Advances in treatment and research in the past few decades have increased the five-year 
survival rate in the early stages of CRC; however, the survival rate has continued to show dismal 
progress in the metastatic stage of the disease. The improvement in the survival rate at earlier 
stages is attributed to surgical resection of the primary tumor followed by adjuvant 
chemotherapy; however metastasis is untreatable, thus emphasizing the need for developing anti-
metastatic therapy. Anti-metastatic therapies might be more effective if they inhibit the survival 
of the cancer cells that have left the primary tumor site and it undergoing metastasis. Drugs 
targeting metastasis have to be used for a long time, thus making them incompetent in the clinic 
due to their known toxic effects. Thus, anti-metastatic therapies need to be designed in such a 
way that they elicit regression of established metastasis so that they qualify for clinical practice. 
6.2.1 Current Standing 
Various studies have been performed to determine the role of Akt isoforms in regulating 
metastases. It is known that Akt2 plays an important role in metastases of CRC cells, which are 
deficient in PTEN. Recent studies have reported a link between PTEN loss, Akt2 overexpression 
and increased metastatic potential of CRC cells. Additionally, it is known that loss of Akt1 and 
Akt2 inhibit the growth of CRC cells. However, we still don’t know the mechanism of inhibition 
of establishment of metastasis by Akt2. The important question addressed in this work is the 
differential role of Akt isoforms in CRC cell survival and the underlying mechanism. 
Additionally, we have also determined the mechanism of Akt 2 affecting the maintenance of 
established metastasis.  
 We have performed orthotopic implantation studies with inducible knockdown of Akt 
isoforms in our CRC cell models. This model recapitulates the pattern of human CRC primary 
and metastatic deposits. We observed 40% reduction in the number of animals with metastasis on 
loss of Akt2. Mechanistically we observed a loss in the expression of XIAP and survivin on loss 
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of Akt isoforms. Additionally, an increase in the expression of AIF was observed on loss of Akt2 
thus leading to increase in cell death.  
 A key and novel finding in this study was the identification of increase in the expression 
of a Metastasis Suppressor gene (MTSS1) on loss of Akt2. MTSS1 is known to promote tumor 
growth by enhancing cell proliferation, invasion and cell migration. MTSS1 has been shown to 
inhibit the expression of pSrc (Tyr 416), which in turn leads to a loss in the phosphorylation of 
Cortactin at Tyr 421. Loss of Akt2 leads to the activation of MTSS1pSrcpCortactin axis 
leading to reduction in metastasis. We also identified that loss of Akt2 leads to the loss of β-
TRCP, a ubiquitin ligase which ubiquitinates MTSS1 thus leading to its proteasomal degradation. 
 The Cancer Genome Atlas showed that in CRC patients there is an increase in the 
expression of Akt2 in comparison to the normal patients, whereas Akt1, Akt3 and MTSS1 
expression decreased in tumor samples. Interestingly we also observed that in primary tumors, 
Akt2 and MTSS1 are negatively correlated. The work presented in this dissertation is novel and 
unique in its own way but it needs to be studied in detail in larger human patient data sets.  
6.2.2 Future directions 
This dissertation reports a novel mechanism of Akt2-mediated increased maintenance of 
established CRC metastasis, thus identifying Akt2 as an important therapeutic target. This study 
emphasizes the need for developing Akt2 specific inhibitors for treating late stage CRC patients, 
who are diagnosed at a stage when cancer has already undergone metastasis. Additionally, the 
Cancer Genome Atlas shows that Akt2 and MTSS1 are negatively correlated in the primary 
tumor samples in CRC. These data help us to postulate that Akt2 high/MTSS1 low expression 
may be a marker for metastatic disease. We also predict that Akt2-MTSS1 negative correlation 
may be used to identify patients that might benefit most from Akt2 mediated therapy. This can be 
confirmed by performing IHC analysis on larger sets of patient sample. 
172 
 
 
 The transwell migration assay shows that loss of Akt1 and Akt3 lead to a reduction in cell 
motility although it is not as robust as compared to Akt2 loss. The PCR array analysis shows that 
there is an increase in the expression of NME-1 on loss of Akt2. NME-1 is a metastatic 
suppressor gene. Currently, there are no studies which show a link between Akt1 and NME-1 
expression in any cancer type. We observed an increase in the expression of NME-1 on loss of 
Akt1 specifically, whereas no change in the expression of this metastatic suppressor gene was 
observed on loss of Akt1 and Akt3. Future studies are needed to determine the mechanism of 
effect of Akt1 loss on NME-1. We also need to understand the downstream signaling of NME-1 
to determine how this molecule affects metastasis.  
 PCR array analysis has helped us to determine the differential expression of various 
metastatic genes on loss of Akt isoforms. We identified a novel mechanism of Akt2 affecting the 
maintenance of established metastasis via MTSS1, although there were certain genes which were 
affected by either two or all the three isoforms. We need to determine the effect of these genes 
and verify their effect on metastasis as well as the underlying mechanism.   
6.3 Final conclusion 
The studies presented in this dissertation have both mechanistic insights and clinical implications. 
This work has shown that Akt2 can be an important therapeutic target that might prevent the 
maintenance of established metastasis. Advancement in research in the past few decades have 
increased the survival rate if CRC is diagnosed at an early stage, however the increase in survival 
rate at late stages is not very impressive. About 20% of CRC cases are diagnosed when the cancer 
has already undergone metastasis thus urging the need to identify molecules that might affect be 
responsible for maintaining metastasis so that they can be targeted therapeutically, thus leading to 
regression of already established metastasis. This dissertation research has identified that Akt2 as 
one of the targets that may be responsible for maintaining metastasis via MTSS1. 
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